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4th International Conference on Radiopharmaceutical Therapy (ICRT 2011)
In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine
(ARCCNM)
28 Nov – 2 Dec 2011, New World Hotel, Ho Chi Minh City, Vietnam
POSTER PRESENTATION
Dear Dr Aisyah Elliyanti,
Thank you for taking time to submit your abstract for the joint meeting of WARMTH’s 4th
International Conference on Radiopharmaceutical Therapy 2011 and the 10th AGM of
ARCCNM.
We are pleased to inform you that your abstract, “Serum Thyroglobulin Level Alone is not
Enough to Monitor Persistence or Recurrence Disease of Differentiated Thyroid
Carcinoma” has been selected for Poster Presentation at the Joint Congress.
(A) POSTER PRESENTATION
You will be provided with a poster board to mount your poster. Please note exact the
maximum permitted dimensions for your poster is as follow:
Poster Size - AO: 1189mm (height) by 841mm (width) or
46.81 inches (height) by 33.11 inches (width)
Posters MUST be in Portrait format and should be put up before 1000hrs on Tuesday, 29
November 2011. Your Poster Number will be indicated on the Poster Boards. Kindly put up
your poster(s) to the Poster Number that is allocated to you. Please note that the width of
the poster board may not be exceeded under any circumstances. Velcro adhesive / Poster
Board Pins will be provided at the conference venue to mount posters on the boards.
(B) JUDGING & RESULTS
All Poster Presentations will be judged by a panel of judges and three posters will be chosen
for First, Second and Third Prizes. You are required to standby at your poster during the Tea
Break Sessions to answer the questions posed by the judges and other participants of the
conference.
Results of the judging will be announced during the Closing Ceremony at the New World
Hotel Conference Hall on Thursday, 1 December 2011.
All presenters are strongly encouraged to attend the Closing Ceremony.
We look forward to your participation in the congress and request you to kindly send a
confirmation note at your earliest convenience.
Regards,
Ee Sia
International Conference on Radiopharmaceutical Therapy Secretariat
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4th International Conference on Radiopharmaceutical Therapy
(ICRT 2011)
In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)
28 Nov – 2 Dec 2011
New World Saigon Hotel, Ho Chi Minh City, Vietnam
Day 1: Monday, 28 November 2011
0800 – 1600 REGISTRATION Ben Thanh Hall Foyer, Level 1
0900 – 1700 NATIONAL COORDINATORS' MEETING OF AN IAEA REGIONALTECHNICAL COOPERATION PROJECT To Be Advised
1200 – 1300 LUNCH / TRADE EXHIBITION
1300 – 1445 PRE-CONGRESS NUCLEAR CARDIOLOGY SYMPOSIUM: SESSION I Ben Thanh Hall 1 & 2, Level 1
Session Chairpersons:
1. Prof Vo Thanh Nhan, Vietnam
2. Prof Henry Bom, CNU Medical School, Korea
1300 – 1330
(O-6)
Myocardial Perfusion Imaging as a Gatekeeper for Coronary Angiography
Dr Carlos D Libhaber, Nuclear Cardiology, University of the Witwaterstrand, Johannesberg, South Africa
1330 – 1400
(O-2)
Clinical Roles of Myocardial Viability Assessment
Prof Zuo-Xiang He, Nuclear Medicine, Fu Wai Hospital & Cardiovascular Institute, Beijing, China
1400 – 1430
(O-3)
Nuclear Medicine in Heart Failure
Dr R Giubbini, Chair of Nuclear Medicine, University of Brescia, Italy (IAEA Expert)
1430 – 1450 ORAL PRESENTATIONS
1430 – 1440
(O-4)
A Custom-Built Software Tool for Data Storage and Analysis of Acquisition and Processing Parameters
For Tc-99m and Tl-201 MPI with Different Imaging Systems
Dr Charalambos Yiannakkaras, Medical Physics, Nicosia General Hospital, Nicosia, Cyprus
1440 – 1450
(O-5)
Construction of a Dynamic Cardiac Phantom to Optimize the Diagnostic Value in SPECT Myocardial
Perfusion Imaging
Dr Yiannis Parpottas, General Department (Physics-Math), Frederick University, Nicosia, Cyprus
1450 – 1500 COFFEE / TEA / TRADE EXHIBITION Ben Thanh Hall FoyerPre-Function Area, Level 1
1500 – 1700 PRE-CONGRESS NUCLEAR CARDIOLOGY SYMPOSIUM: SESSION II Ben Thanh Hall 1 & 2, Level 1
Session Chairpersons:
1. Dr Bùi Diệu Hằng, Vietnam 
2. Dr Vikram Lele, Nuclear Medicine & PET-CT, Jaslok Hospital & Research Centre, Mumbai, India
1500 – 1530
(O-1)
Direct Myocardial Ischemia Imaging
Prof Zuo-Xiang He, Nuclear Medicine, Fu Wai Hospital & Cardiovascular Institute, Beijing, China
1530 – 1600
(O-7)
Multimodality Assessment of Myocardial Ischemia and Viability – Part 1 (CT/MRI/Echo)
Dr Felix Keng, Nuclear Cardiology, National Heart Centre, Singapore
1600 – 1630
(O-8)
Multimodality Assessment of Myocardial Ischemia and Viability – Part 2 (SPECT & PET)
Prof Henry Bom, CNU Medical School, Korea
1630 – 1700 Discussions
1730 – 1830 WARMTH GOVERNING BODY MEETING (GOVERNING BODY MEMBERS ONLY)
1930 – 2200 WELCOME DINNER Grand Mekong Ballroom,Level 1
2200 END OF DAY 1
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4th International Conference on Radiopharmaceutical Therapy
(ICRT 2011)
In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)
28 Nov – 2 Dec 2011
New World Saigon Hotel, Ho Chi Minh City, Vietnam
Day 2: TUESDAY, 29 November 2011
0730 – 1600 REGISTRATION Ben Thanh Hall Foyer, Level 1
0800 – 0815 OPENING REMARKS
0815 – 0955 SCIENTIFIC SESSION I: THYROID I Ben Thanh Hall, Level 1
Session Chairpersons:
1. Prof Adil Al-Nahhas, Nuclear Medicine, Imperial College, London, United Kingdom
2. Dr Tran Van Thiep, Vietnam
0815 – 0840
(O-9)
Radioiodine Therapy of Thyroid Cancer at Seoul National University (SNU) Hospital
Prof June-Key Chung, Nuclear Medicine, Seoul National University Hospital, Seoul, Korea
0840 – 0905
(O-10)
Thyroid Cancer and the Benefit of rhTSH in Treatment
Dr Knut Liepe, Nuklearmedizin, Klinikum Kassel, Germany
0905 – 0930
(O-11)
Thyroid Cancer: Anything New?
Prof Irene Virgolini, Nuclear Medicine & PET, Medical University of Innsbruck, Innsbruck, Austria
0930 – 0955
(O-12)
Eurasian Federation of Oncology: Ventures for Collaboration with WARMTH
Dr Somasundaram Subramanian, Director, Eurasian Federation of Oncology, Surgeon (Head & Neck,
Melanoma), Department of Biotherapy, N. N. Blokhin Russian Cancer Research Center, Moscow, Russia
0955 – 1015 ORAL PRESENTATIONS Ben Thanh Hall, Level 1
0955 – 1005
(O-13)
Effect of Short Term Metformin Therapy Associated with Levothyroxin Dose Decrement on TSH and
Thyroid Hormone Levels in Patients with Thyroid Cancer
Dr Seyed Rasoul Zakavi, Nuclear Medicine Research Center, Emam Reza Hospital /
Mashhad University of Medical Sciences, Mashhad, Iran
1005 – 1015
(O-14)
Breast Cancer and Autoimmune Thyroiditis: Does the Sodium Iodide Symporter Play a Role?
Dr Jefferson Pagsisihan, Nuclear Medicine, St. Lukes Hospital, Quezon City, Philippines
1015 – 1100 COFFEE / TEA / TRADE EXHIBITION Ben Thanh Hall FoyerPre-Function Area, Level 1
1015 – 1100 POSTER PRESENTATIONS: THYROID DISEASES Ben Thanh Hall FoyerPre-Function Area, Level 1
Session Coordinators:
1. Dr Ngo Thuy Trang, MD,The Nuclear Medicine and Oncology Center, Hanoi, Vietnam
2. Dr Duong Duc Binh, Nuclear Medicine, Danang Hospital, Danang City, Vietnam
(P-1) Is 99Tcm Thyroid Planar Imaging Suitable for Evaluating Residue Thyroid after Thyroidectomy: Comparing
with I131 Scan after Radioiodine Therapy
Dr Shuqi Wu, Nuclear Medicine, Xinhua Hospital, Shanghai Jiaotong University, Shanghai, China
(P-2) Tc-99m MIBI Scintigraphy For Post-Therapy Differentiated Thyroid Carcinoma Patients Follow Up
Dr Ryan Yudistiro, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia
(P-3) Effect of I-131 Large Dose Thyroid Carcinoma Therapy on Sub Mandibular & Parotid Gland.
Quantitative Analysis of Salivary Excretion Pre and Post Therapy
Dr Om Prakash Sinha, Nuclear Medicine, Gujrat Cancer & Research Institute, Ahmedabad, India
(P-4) Serum Thyroglobulin Level Alone is not Enough to Monitor Persistence or Recurrence Disease of
Differentiated Thyroid Carcinoma
Dr Aisyah Elliyanti, Radiology / Nuclear Medicine, Dr M Djamil Hospital / Faculty of Medicine Andalas University,
Padang, Indonesia
(P-5) Pattern of Metastases in Well Differentiated Thyroid Microcarcinoma
Dr Fithriany Syamsuddin, Nuclear Medicine, Dr Hasan Sadikin Hospital /
Padjajaran University, Bandung, Indonesia
(P-6) Outcame of Pregnancy after Radioactive Iodine Treatment
Dr Dessie Yulistiawaty, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia
(P-7) Radioactive Iodine Ablation in Young Adults With Differentiated Thyroid Carcinoma
Dr Yustia Tuti Jelani, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia
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4th International Conference on Radiopharmaceutical Therapy
(ICRT 2011)
In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)
28 Nov – 2 Dec 2011
New World Saigon Hotel, Ho Chi Minh City, Vietnam
Day 2: TUESDAY, 29 November 2011 (cont’d)
(P-8) Applications of Nuclear Medicine Techniques in Diagnosis and Treatment of Differentiated Thyroid
Carcinoma: Results in Vietnam
Dr Phan Sy An An, Nuclear Medicine& Oncology, Bach Mai, Hanoi, Vietnam
(P-9) Differentiated Thyroid Cancer Ablation: 5 Years Experience in Limassol General Hospital
Dr Ourania Demetriadou, Nuclear Medicine, Limassol General Hospital, Limassol, Cyprus
(P-10) Efficiency Predictive Factors of Radio-Iodine Ablation in Differentiated Thyroid Cancer
Dr Chatti Kaouthar, Nuclear Medicine, Sahloul University Hospital, Sousse, Tunisia
(P-11) Lymph Node Metastasis of Differentiated Thyroid Cancer More Frequently Develops into Non-Iodine-Avid
Than Lung or Bone Metastasis
Dr Fang Feng, Nuclear Medicine, Xinhua Hospital, Shanghai, China
(P-12) The Outcome of 23 Patients Differentiated Thyroid Carcinoma with Lung Metastase After
Radiothyroablation with Iodine-131
Dr Gani Gunawan, Nuclear Medicine, Hasan Sadikin General Hospital, Bandung, Indonesia
(P-13) Head Mass with Radioactivity Uptake in Patient with Thyroid Carcinoma
Dr Nopriwan Agamawan Salam, Nuclear Medicine, Hasan Sadikin Hospital, Bandung, Indonesia
(P-14) Recent Status of Radioiodine Therapy for Patients with Primary Hyperthyroidism and Differentiated
Thyroid Carcinoma in Bangladesh
Dr Shahana Afroz, Biological Science, Bangladesh Atomic Energy Commission, Dhaka, Bangladesh
(P-15) Role of Ultrasonography (USG), Radionuclide Scan (RNS) and Fine Needle Aspiration Cytology (FNAC) in
Thediagnosis of Malignancy in Solitary Thyroid Nodule
Dr Akhter Nahid, Nuclear Medicine, Centre for Nuclear Medicine & Ultrasound, Dinajpur, Dhaka, Bangladesh
(P-16) Unusual Metastasis in Papillary Thyroid Carcinoma: A Case Report
Dr Hapsari Indrawati, Nuclear Medicine, Hasan Sadikin Hospital, Bandung, Indonesia
(P-17) Effect of Low Dose Radioiodine Therapy in Respect to Amount of Post-Operative Thyroid Tissue
(With Metastasis or Not)
Dr AKM Fazlul Bari, Thyroid Medicine, Institute of Nuclear Medicine and Ultrasound, Dhaka, Bangladesh
(P-18) I-131 Therapy for Pediatric Hyperthyroid; A Clinical Experience in Nuclear Medicine Department,
Dr Hasan Sadikin Hospital, Indonesia
Dr Erwin Affandi Soeriadi, Nuclear Medicine, Dr Hasan Sadikin Hospital, Indonesia
(P-19) Quantitative Study of the Different Protocols Analysis for Excess Radiation Absorbed Doses from
Radioiodine Treatment of Hyperthyroidism in Bangladesh
Dr Md Nahid Hossain, Institute of Nuclear Medicine & Ultrasound, Dhaka, Bangladesh
(P-20) Thyroid Functional Status in Chronic Kidney Disease (CKD)
Dr Mosharruf Hossain, Nuclear Medicine, Rajshahi Medical College Hospital, Rajshahi, Bangladesh
(P-21) Effect of Single Dose of Radioiodine Therapy on Volume Reduction of Thyroid Gland in Hyperthyroidism
Dr Shamrukh Khan, Institute of Nuclear Medicine & Ultrasound, Dhaka, Bangladesh
(P-22) Graded Empirical I-131 Therapy in Differentiated Thyroid Cancer – Is There an Ideal Dose?
Dr Ajit Shinto, Nuclear Medicine and PET, KMCH, Coimbatore, India
(P-23) Role of Tc-99m Pertechnetate Thyroid Scintigraphy in Detecting Etiology of Congenital Hypothyroidism
Dr Aulia Huda Buchori, Dr Hasan Sadikin Hospital / Padjadjaran University, Bandung, Indonesia
(P-24) Incremental Value of 131I-SPECT/CT Fusion Imaging Over 131I-WBS in the Management of Patients with
Differentiated Thyroid Carcinoma
Dr Ye Zhi-Yi, Nuclear Medicine, Xinhua Hospital, Shanghai Jiaotong University, Shanghai, China
(P-25) Empirical Dual Dose Iodine-131 Therapy for Graves’ Disease
Dr Khalid Makhdomi, Radiology, Aga Khan University Hospital, Nairobi, Kenya
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4th International Conference on Radiopharmaceutical Therapy
(ICRT 2011)
In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)
28 Nov – 2 Dec 2011
New World Saigon Hotel, Ho Chi Minh City, Vietnam
Day 2: TUESDAY, 29 November 2011 (cont’d)
(P-26) Complications to the Mother and Child with Thyroid Cancer after the Treatment with I-131
Prof Sassan Saber, Nuclear Medicine, Shariati Hospital, Tehran, Iran
(P-27) Lacrimal Duct Obstruction after Iodine-131 Therapy in Patients with Differentiated Thyroid Cancer
Prof Abbas Takavar, Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
(P-28) Comparison of Different Techniques for Assessment of Thyroid Functional Status in Patients with
Hyperthyroidism
Dr Qaisar Siraj, Nuclear Medicine, Farwania Hospital Kuwait, Kuwait
(P-29) The Advantages of Routine Radiothyroablation in Well Differentiated Thyroid Carcinoma Patients
Dr Hapsari Indrawati, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia
(P-30) Electrolyte Imbalance in Patients During Radioablation Na I-131
Dr Aulia Huda Buchori, Nuclear Medicine, Dr Hasan Sadikin Hospital / Padjadjaran University, Bandung, Indonesia
(P-31) Theurapeutical Response Evaluation on Hyperthyroidism Using a Fixed Dosed of I-131
Dr Yulia Kurniawati Burhanuddin, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia
(P-32) Influence of Metastases Characteristic to Survival Rate in Papillary Thyroid Carcinoma
Dr Nopriwan Agamawan Salam, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia
(P-33) Pattern of Lung Metastases and its Influence to DTC Treatment Outcome
Dr Gani Gunawan, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia
(P-34) Assessment of Organification Defect in Thyroid Gland in Children with Goitrous Hypothroidism
Dr Anirudhan Narasimhan, Nuclear Medicine, G.K.N.M Hospital, Coimbatore, India
(P-35) Nal-131 Radio Ablation for Well Differentiated Thyroid Cancer at Dr Hasan Sadikin General Hospital
Dr Dodi Nugraha, Nuclear Medicine, Dr Hasan Sadikin Hospital, Bandung, Indonesia
(P-36) Significance of Raised Anti Thyroglobulin Antibody Levels in Diffrentiated Thyroid Cancer Patients
Dr Javaid Irfan, Nuclear Medicine Oncology and Radiotherapy Institute (NORI), Islamabad, Pakistan
(P-37) Rare Case of Metastasis to Pituitary from Follicular Thyroid Carcinoma
Dr Butch Magsombol, Nuclear Medicine and PET, Singapore General Hospital, Singapore
(P-38) Efficacy of I-131 Therapy in the Treatment of Differentiated Thyroid Carcinoma: Results in 655 Patients
Treated at the Nuclear Medicine Department of Bach Mai Hospital, Hanoi
Prof Mai Trong Khoa, Nuclear Medicine, Bach Mai Hospital, Hanoi, Vietnam
Dr Trang Ngo, Nuclear Medicine, Bach Mai Hospital, Hanoi, Vietnam
(P-39) Radionuclide Therapy in Russia. A Status Report from the Largest Radionuclide Therapy Centre in Russia
Prof Valeriy Krylov, Radionclide Therapy Department, Medical Radiological Research Center, Obninsk, Russia
1100 – 1240 SCIENTIFIC SESSION 2: THYROID II Ben Thanh Hall, Level 1
Session Chairpersons:
1. Dr Nguyen Thi Bich Dao, Vietnam
2. Prof Leszek Krolicki, Nuclear Medicine, Medical University of Warsaw, Poland
1100 – 1120
(O-15)
Radioiodine Therapy of Differentiated Thyroid Cancer: A Review
Dr Savvas Frangos, Nuclear Medicine, Bank of Cyprus Oncology Center, Strovolos, Nicosia, Cyprus
1120 – 1140
(O-16)
Guidelines for Treatment of Differentiated Thyroid Carcinoma: A Critical Appraisal
Prof Jasna Mihailovic, Nuclear Medicine, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia
1140 – 1200
(O-17)
Radioiodine Treatment of Hyperthyroidism: A Review
Dr Emerita Barrenechea, Nuclear Medicine, Veterans Memorial Medical Centre, Quezon City, Philippines
1200 – 1220
(O-18)
Graves' Ophthalmopathy
Dr Wong Wai Yin, Nuclear Medicine, Singapore General Hospital, Singapore
1220 – 1240
(O-19)
Thyromomics
Dr A Velumani, Thyrocare Technologies Ltd, Turbhe, Navi Mumbai, India
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4th International Conference on Radiopharmaceutical Therapy
(ICRT 2011)
In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)
28 Nov – 2 Dec 2011
New World Saigon Hotel, Ho Chi Minh City, Vietnam
Day 2: TUESDAY, 29 November 2011 (cont’d)
1240 – 1300 ORAL PRESENTATIONS Ben Thanh Hall, Level 1
1240 – 1250
(O-20)
The Assessment of Oxidative Stress and Hematological Changes in Patients with Differentiated Thyroid
Carcinoma Treated with Radioiodine
Prof Milovan Matovic, Nuclear Medicine, Clinical Centre Kragujevac, Kragujevac, Serbia
1250 – 1300
(O-21)
Relationship Between Radiation Absorbed Dose to the Blood and Successful Ablative Treatment in
Thyroid Cancer Patients
Dr Shazia Fatima, Nuclear Medicine, Oncology & Radiotherapy Institute Islamaba, Islamabad, Pakistan
1300 – 1400 LUNCH / TRADE EXHIBITION
1400 – 1505 SCIENTIFIC SESSION 3: BONE PAIN & RADIOSYNOVECTOMY Ben Thanh Hall, Level 1
Session Chairpersons:
1. Dr Emerita Barrenechea, Nuclear Medicine, Veterans Memorial Medical Centre, Quezon City,
Philippines
2. Dr Qaisar Siraj, Nuclear Medicine, Farwania Hospital Kuwait, Kuwait
1400 – 1425
(O-22)
Radiosynovectomy in the Treatment of Arthritis
Dr Knut Liepe, Nuklearmedizin, Klinikum Kassel, Germany
1425 – 1445
(O-23)
Use of Re-188 Colloid in Radiosynovectomy: Experience at AIIMS
Prof Rakesh Kumar, Nuclear Medicine & PET, All India Institute of Nuclear Medicine, India
1445 – 1505
(O-23A)
Radiosynoviorthosis (Radiation Synovectomy): State of the Art 2011
Prof Gynter Moedder, German Centre for Radiosynoviorthesis, Cologne, Germany
1505 – 1545 ORAL PRESENTATIONS Ben Thanh Hall, Level 1
1505 – 1515
(O-25)
Intra-Articular Evaluation of Lu-177 Hydroxyapatite in Animal Model
Dr Muhammad Sohaib, Medical Sciences, Pakistan Institute of Engineering and Applied Science (PIEAS),
Islamabad, Pakistan
1515 – 1525
(O-26)
Development of Colloidal Samarium Phosphate [32P] Injection for Radiation Synovectomy-A New
Therapeutic Radiopharmaceutical Agent For The Treatment Of Joint Disorders
Dr Prabhakar Ganti, Department of Atomic Energy (DAE), Board of Radiation & Isotope Technology,
Navi Mumbai, India
1525 – 1535
(O-27)
Optimal Timing of Biphosphonate Therapy in Combination with Samarium-153 Therapy in Metastatic Bone
Disease
Dr Nigora Rasulova, Nuclear Medicine, Republic Specialized Center of Surgery, Tashkent, Uzbekistan
1535 – 1545
(O-28)
Evaluation of P-32 for Bone Pain Palliation in Prostate Cancer with Skeletal Metastases
Dr Muhammad Aleem Khan, Nuclear Medicine, Nuclear Medicine Oncology and Radiotherapy Institute (NORI),
Islamabad, Pakistan
1545 – 1600 COFFEE / TEA / TRADE EXHIBITION Ben Thanh Hall FoyerPre-Function Area, Level 1
POSTERS PRESENTATION: BONE PAIN PALLIATION /
RADIOSYNOVECTOMY
Ben Thanh Hall Foyer
Pre-Function Area, Level 1
Session Coordinators:
1. Dr Vo Khac Nam, Vietnam
2. Dr Tran Song Toan, Nuclear Medicine , Cho Ray Hospital, Ho Chi Minh, Vietnam
(P-40) Detection of Bone Metastases by Planer Bone Scintigraphy and SPECT Bone Scintigraphy
Dr MD Sayedur Rahman Miah, Centre for Nuclear Medicine & Ultrasound, Bangladesh Atomic Energy
Commission, Comilla, Bangladesh
(P-41) Our First Experiences in Palliative Treatment of Painful Bone Metastases with Sm-153
Dr Zvezdana Rajkovaca, Nuclear Medicine, Clinical Center Banja Luka, Banja Luka, Bosnia & Herzegovina
(P-42) Evaluation of Prostate Cancer with Serum Prostate Specific Antigen, Alkaline Phosphatase Level and
Bone Scintigraphy
Dr Afroz Shirin, Scintigraphy, Institute of Nuclear Medicine & Ultrasound, Dhaka, Bangladesh
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4th International Conference on Radiopharmaceutical Therapy
(ICRT 2011)
In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)
28 Nov – 2 Dec 2011
New World Saigon Hotel, Ho Chi Minh City, Vietnam
Day 2: TUESDAY, 29 November 2011
(P-43) Bone Scintigraphy Findings of Multiple Osteoblastic Lesions in a Child with
Primitive Neuroectodermal Tumor
Dr Karina Michaela Dela Cruz, Nuclear Medicine, University of Santo Tomas, Manila, Philippines
(P-44) Bone-Seeking Radiopharmaceuticals for Pain Palliation in Prostate Cancer Metastasis
Dr Raluca Mititelu, Nuclear Medicine, Central University Military Hospital Bucharest, Bucharest, Romania
(P-45) Present Day Utility of Whole Body Bone Scan in Evaluating Silent Skeletal Metastases in Apparently
Operable Non Small Cell Lung Cancer when PET is not Available
Dr Ajit Shinto, Nuclear Medicine and PET, KMCH, Coimbatore, India
(P-46) 89Sr Bremsstrah Lung SPECT Imaging in Bone Metastases
Dr Masanobu Ishiguro, Section of Radiology Division of Nuclear Medicine, Fujita Health University Hospital,
Toyoake, Japan
(P-47) Comparison of the Value of 18 F-FDG PET And 99 Tcm-MDP Bone Scan in the Detection of Bone
Metastases
Dr Shuqi Wu, Nuclear Medicine, Xinhua Hospital,Shanghai Jiaotong University, Shanghai, China
(P-48) Current Status of Radionuclide Therapy in Indonesia
Dr Alvita Dewi Siswoyo, Nuclear Medicine, RS Dr Hasan Sadikin, Bandung, Indonesia
(P-49) Effectiveness of Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal
Antibody Denosumab (Xgeva)
Dr Nigora Rasulova, Nuclear Medicine, Republic Specialized Center of Surgery, Tashkent, Uzbekistan
1600 – 1730 SCIENTIFIC SESSION 4: RADIOPHARMACY / GENERAL NUCLEAR MEDICINE Ben Thanh Hall, Level 1
Session Chairpersons:
1. Prof Alan Perkins, Radiological and Imaging Sciences, Nottingham University Hospital, Nottingham,
United Kingdom,
2. Prof Azu Owunwanne, Nuclear Medicine, Faculty of Medicine, Kuwait University, Safat, Kuwait
1600 – 1625
(O-29)
Theragnostic Radiopharmaceuticals: An Emerging Paradigm Empowering Personalized Medicine
Dr Suresh Srivastava, Collider-Accelerator Department, Brookhaven National Laboratory, Upton, NY USA
1625 – 1640
(O-30)
ONCIDIUM Foundation: A Perspective
Dr Richard Zimmermann, IBA, Molecular, IBA, Louvain-La-Neuve, Belgium
1640 – 1700
(O-31)
Regulatory Aspects of Therapeutic Radiopharmaceuticals
Dr Maung Maung Saw, Clinical Imaging Research Centre, National University of Singapore, Singapore
1700 – 1720
(O-32)
Clinical Applications of SPECT/CT in Oncology
Dr Sonia Sergieva, Nuclear Medicine, Sofia Cancer Centre, Sofia, Bulgaria
1720 – 1800
(O-33)
Radiopharmaceutical And Molecular Therapy Quiz
(Three Prizes for 3 Participants Scoring Highest Scores)
Dr Gopinath Gnanasegaran, Nuclear Medicine, Guys & St Thomas' Hospital NHS Foundation Trust, St Thomas
Hospital, London, United Kingdom
1900 – 2300 FORMAL INAUGURATION OF THE CONFERENCE & GALA DINNER Grand Mekong Ballroom,Level 1
2300 END OF DAY 2
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4th International Conference on Radiopharmaceutical Therapy
(ICRT 2011)
In Conjunction with 10th AGM of Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)
28 Nov – 2 Dec 2011
New World Saigon Hotel, Ho Chi Minh City, Vietnam
Day 3: WEDNESDAY, 30 November 2011
0800 – 1020 SCIENTIFIC SESSION 5: GI TRACT CANCER / LIVER CANCER Ben Thanh Hall, Level 1
Session Chairpersons:
1. Dr Patricia Bernal Trujillo, Fundacion Santa Fe, Bogota, Colombia
2. Prof Harvey Turner, University of Western Australia, Fremantle Hospital, Australia
0800 – 0825
(O-34)
Targeted Chemoradiation in Metastatic Colorectal Cancer: A Phase I Trial of 131I-Hua33 with Concurrent
Capecitabine
Prof Andrew Scott, Centre for PET, Austin Hospital, Heidelberg, Australia
0825 – 0850
(O-35)
Targeted Radionuclide Therapy of Liver Tumors
Prof Gregory Wiseman, Radiology, Mayo Clinic, Rochester, USA
0850 – 0915
(O-36)
Radiological and Clinical Efficacy of Radio-embolization (Re) Using 188Re HSA-microspheres in Patients
with Advanced, Primary or Metastatic Liver Cancer
Dr Jaroslaw Cwikla, Radiology and Diagnostic Imaging, Postgraduate Medical Centre and Central Clinical Hospital,
Warsaw, Poland
0915 – 0935
(O-37)
PET is Superior to CT in Assessing Response to SIRT in Liver Tumours
Prof Adil Al-Nahhas, Nuclear Medicine, Imperial College, London, United Kingdom
0935 – 0955
(O-38)
Molecular Radiotherapy in the UK: The Current Status
Prof John Buscombe, Nuclear Medicine, Royal Free Hospital, Cambridge, United Kingdom
0955 – 1020
(O-39)
Statistics – OR, RR and HR
Prof Janez Stare, Faculty of Medicine, University of Ljubljana, Slovenia
1020 – 1030 ORAL PRESENTATIONS Ben Thanh Hall, Level 1
1020 – 1030
(O-40)
Does Clinical Outcome In Hepatic Y-90 Microsphere Therapy Depends On Correlation Between Y-90 and
Tc-99m MAA Distributions?
Dr Karin Knesaurek, Radiology / Nuclear Medicine, Mount Sinai Medical Center, New York, USA
1030 – 1100 COFFEE / TEA / TRADE EXHIBITION
Ben Thanh Hall Foyer
Pre-Function Area, Level 1
1030 – 1100 POSTER PRESENTATIONS: MOLECULAR IMAGING, RADIOPHARMACY Ben Thanh Hall FoyerPre-Function Area, Level 1
Session Coordinators:
1. Dr Butch Magsombol, Nuclear Medicine and PET, Singapore General Hospital, Singapore
2. Dr Nigora Rasulova, Nuclear Medicine, Republic Specialized Center of Surgery, Tashkent, Uzbekistan
(P-50) Normal Uptake Value of C-11 Acetate in Some Organs
Dr Thi Minh Chau Trinh, Nuclear Medicine, University Medical Center, Ho Chi Minh City, Vietnam
(P-51) Development of Nanoradiopharmaceuticals
Dr Ralph Santos-Oliveira, Laboratory of Nanoradiopharmaceuticals, University Hospital Clementino Fraga Filho,
Rio de Janeiro, Brazil
(P-52) Nanoradiopharmaceuticals: Development of Labeling Process
Dr Ralph Santos-Oliveira, Laboratory of Nanoradiopharmaceuticals, University Hospital Clementino Fraga Filho,
Rio de Janeiro, Brazil
(P-53) Synthesis, Radio Labeling and Biological Evaluation of [67Ga]- 5,10,15,20-Tetrakis(Pentafluorophenyl)
Porphyrin Complexe as an Imaging Agent
Dr Mohammad Reza Aboudzadeh Rovais, Nuclear Medicine Research Group, Agricultural, Medical and Industrial
Research School, Karaj, Iran
(P-54) Synthesis, Radiolabeling and Biological Evaluation of [111In]-Maltolate Complex as an Imaging Agent
Prof Yousef Fazaeli, Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School
(AMIR), Karaj, Iran
(P-55) Production, Quality Control and Imaging of 64Cu-ATSM in Healthy Rabbits for Clinical Applications
Prof Yousef Fazaeli, Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School
(AMIR), Karaj, Iran
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Day 3: WEDNESDAY, 30 November 2011 (cont’d)
(P-56) Synthesis, Radiolabeling and Biological Evaluation of [67Ga]-Maltolate Complex as an Imaging Agent
Prof Yousef Fazaeli, Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School
(AMIR), Karaj, Iran
(P-57) Preparation and Evaluation of [67Ga]-Tetra Phenyl Porphyrin Complexes as Imaging Agents
Prof Yousef Fazaeli, Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School
(AMIR), Karaj, Iran
(P-58) Radiosynthesis and Biological Evaluation of [111In]-5,10,15,20-Tetrakis(Pentafluorophenyl) Porphyrin
Complex as a Possible Imaging Agent
Dr Mohammad Reza Aboudzadeh Rovais, Nuclear Medicine Research Group, Agricultural, Medical And Industrial
Research School, Karaj, Iran
(P-59) Emergency Handling in a Medical Cyclotron Facility
Dr Rajeev Kumar, PET Scan Centre , Medical Cyclotron Facility, Army Hospital Research And Referral,
New Delhi, India
(P-60) Development and Evaluation of New Protocol for Synthesis of 6-(18F) Fluoro-L-DOPA
Dr Rajeev Kumar, PET Scan Centre , Medical Cyclotron Facility, Army Hospital Research And Referral,
New Delhi, India
(P-61) AFP-Combined 18F-FDG PET/CT Detection of HCC and its Recurrence
Dr Wu Shuqi, Nuclear Medicine, Xinhua Hospital, Shanghai Jiaotong University, Shanghai, China
(P-62) Simple, Reliable and Cost Effective Radiochemical Purity Test Technique for N-13 Ammonia
Dr Dhananjay Kumar Singh, Nuclear Medicine, Army Hospital Research And Refferal, New Delhi, India
(P-63) 99mtc-Doxorubicin Labeling and its Pre-Clinical Evaluation as a Potential Scintigraphic Probe For Tumor
Imaging
Dr Baljinder Singh, Nuclear Medicine, PGIMER, Chandigarh, India
(P-64) Engineering Salmonella Typhimurium to Become a Dual Purpose-Probe for Therapeutic and in Vivo
Monitoring Applied in Cancer or Myocardial Infarction
Dr Vu Hong Nguyen, Nuclear Medicine, CNU Hwasun Hospital, Hwasun, South Korea
(P-65) Preliminary Results of Various Pegylated I-RGD Peptides for Animal PET-Imaging
Prof Aapo Ahonen, Physiology And Nuclear Medicine, HUSLAB/HUCH, Helsinki, Finland
(P-66) Medical Cyclotron: Accidental Scenarios and Analysis
Dr Nguyen Tan Chau, Unit of PET-CT & Cyclotron, Cho Ray Hospital, Ho Chi Minh, Vietnam
(P-67) To Establish a Synthesis Protocol of 68Gallium-DOTANOC Using 0.05MHCI as Eluant of 68Ge/68Ga
Generator for PET Imaging of Neuroendocrine Tumors (NETS)
Dr Snehlata Lata, Nuclear Medicine & PET, All Institute of Medical Sciences, New Delhi, India
(P-68) Production of Radiopharmaceutical F-18 FDG and C-11 Acetate Using Cyclotron 11 Mev at Cho Ray
Hospital
Dr Truong Ka My Dang, PET-CT & Cyclotron, Cho Ray Hospital, Ho Chi Minh, Vietnam
(P-69) Radionuclide Imaging for Neuroendocrine Tumours: Experience of Singapore General Hospital (SGH), The
Largest Acute Tertiary Hospital in Singapore
Dr Thang Sue Ping, Nuclear Medicine and PET, Singapore General Hospital, Singapore
(P-70) Cyclotron Production of 99mtc in Canada
Dr Erik Van Lier, Targetry and Radiochemistry, Advanced Cyclotron Systems Inc, Richmond, Canada
(P-71) Diagnosis of Pulmonary Neuroendocrine Tumors with 99mtc-Tectrotide (99mtc-HYNIC –TOC) SPECT/CT
and 18F-FDG PET-CT in the Selection of the First Line of Treatment and Determining Staging and
Restaging
Dr Norbert Szalus, Nuclear Medicine, Military Institute of Medicine, Warsaw, Polska
(P-71A) Peptide Receptor Radionuclide Therapy (PRRT): Colombia Experience
Dr Patricia Bernal Trujillo, Nuclear Medicine, Fundacion Santa fe de Bogota, Bogota, Colombia
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1100 – 1230 SCIENTIFIC SESSION 6: NEUROENDOCRINE TUMORS I Ben Thanh Hall, Level 1
Session Chairpersons:
1. Prof John Buscombe , Nuclear Medicine, Royal Free Hospital, Cambridge, UK
2. Prof Andrew Scott, Centre For PET, Austin Hospital, Heidelberg, Australia
1100 – 1125
(O-41)
Peptide Receptor Radionuclide Therapy – The Innsbruck Experience
Prof Irene Virgolini, Nuclear Medicine & PET, Medical University Of Innsbruck, Innsbruck, Austria
1125 – 1150
(O-42)
Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors – The Bad Berka Experience After 10
Years in Over 1000 Patients
Prof Richard Baum, Department of Nuclear Medicine, Center for PET/CT, Bad Berka, Germany
1150 – 1205
(O-43)
PRRT-Experience at Jaslok Hospital
Dr Vikram Lele, Department of Nuclear Medicine & PET-CT, Jaslok Hospital & Research Centre, Mumbai, India
1205 – 1220
(O-44)
Ga-68 DOTATATE Imaging & PRRT in South Africa
Dr Carlos D Libhaber, Nuclear Cardiology, University of the Witwaterstrand, Johannesberg, South Africa
1220 – 1235
(O-24)
New DOTA-Based Bisphosphonate Ligands for PET/CT and Endoradiotherapy of Bone Metastases
Dr Achim Reibel, University of Mainz, Institute of Nuclear Chemistry, Mainz, Germany
1235 – 1300 ORAL PRESENTATIONS Ben Thanh Hall, Level 1
1235 – 1245
(O-45)
90Y And 177Lu – Radionuclides for Peptide Receptor Radionuclide Therapy
Dr Dariusz Pawlak, Research and Development, Institute of Atomic Energy POLATOM, Otwock, Poland
1245 – 1255
(O-46)
Early Prediction of Tumor Response in GEP NET by the Sequential Change of Absorbed Doses During
Treatment with Lu177-Octreotate
Dr Ezziddin Samer, MD, Nuclear Medicine, University Bonn, Bonn, Germany
1255 – 1305
(O-47)
Effect of Peptide Receptor Radionuclide Therapy (PRRT) with Tandem Isotopes- 90Y/ 177Lu-DOTATATE in
Patients wth Disseminated Neuroendocrine Tumors Depending on Qualification PET/CT with 18FDG
Dr Jolanta Kunikowska, Medical University Of Warsaw, Nuclear Medicine Department, Medical University Of
Warsaw, Warsaw, Poland
1305 – 1400 LUNCH / TRADE EXIBITION
1400 – 1510 SCIENTIFIC SESSION 7: NEUROENDOCRINE TUMORS II Ben Thanh Hall, Level 1
Session Chairperson:
1. Prof Sobhan Vinjamuri, Nuclear Medicine, Royal Liverpool University Hospital,
Liverpool, United Kingdom
2. Dr Cornelis Hoefnagel, Division of Diagnostic Oncology, The Netherlands Cancer Institute, The
Netherlands
1400 – 1425
(O-48)
Combined Modality Radiopeptide Therapy of Neuroendocrine Tumours
Prof Harvey Turner, University Of Western Australia, Fremantle Hospital, Australia
1425 – 1450
(O-49)
PRRT: The Italian Experience
Prof Giovanni Paganelli, Divisione Di Medicina Nucleare, IEO Istituto Europeo Di Oncologia, Milano, Italy
1450 – 1510
(O-50)
Meta-Analysis of Radionuclide Therapy in NETs
Dr Shaunak Navalkissoor, Nuclear Medicine, Royal Free Hospital NHS Trust, London, United Kingdom
1510 – 1530 ORAL PRESENTATIONS Ben Thanh Hall, Level 1
1520 – 1530
(O-51)
Tc-Carbonyl Based Octreotide Derivatives
Dr Guhlke Stefan, Nuclear Medicine, University of Bonn, Bonn, Germany
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Day 3: WEDNESDAY, 30 November 2011 (cont’d)
1530 – 1600 POSTERS PRESENTATIONS:GENERAL NUCLEAR MEDICINE & MISCELLANEOUS (ARCCNM)
Ben Thanh Hall Foyer
Pre-Function Area, Level 1
Session Coordinators:
1. Dr Marika Vereb, Nuclear Medicine Department, Klinikum Kassel, Kassel, Germany
2. Ms Nguyen Thi Kim Dung, Vietnam
(P-72) Gamma Camera Based GFR Measurement as an Alternative to 24 Hours Urinary Creatinine Clearance in
Healthy Kidney Donors
Dr Tania Ahmed Ahmed, Nuclear Medicine & Ultrasound, Centre For Nuclear Medicine & Ultrasound, Chittagong,
Chittagong, Bangladesh
(P-73) Differences in Decline in GFR with Age Between Males and Females. Reference Data on 24 Hours Urinary
Creatinine Clearance and DTPA Clearance
Dr Tania Ahmed Ahmed, Nuclear Medicine & Ultrasound, Centre For Nuclear Medicine & Ultrasound, Chittagong,
Chittagong, Bangladesh
(P-74) Preparation and Bio Distribution of 99mtechnetium-Annexin V for In Vivo Detection of Apoptosis
Dr Saeed Rajabifar, Nuclear Medicine, AMIRS, Karaj, Iran
(P-75) Ciprofloxacin Labeling by 99mtechnetium and its Bio Distribution in Normal and Infected Animals
Dr Saeed Rajabifar, Nuclear Medicine, AMIRS, Karaj, Iran
(P-76) Production and Quality Control of 99mtechnetium-Igg-Hynic for Infection Imaging in Experimental Rats
Dr Saeed Rajabifar, Nuclear Medicine, AMIRS, Karaj, Iran
(P-77) Diagnosing Multifocal Tuberculosis in Children with Tc-99m Ethambutol Scintigraphy: A Case Report
Dr Alvita Dewi Siswoyo, Nuclear Medicine, RS Dr Hasan Sadikin, Bandung, Indonesia
(P-78) A Comparative Study of Dobutamine Stress Myocardial Perfusion Imaging and Dobutamine Stress
Echocardiography in the Detection of Coronary Artery Disease in Female Patient – Initial Experience
Dr Nasreen Sultana Nasreen, Nuclear Medicine, Institute of Nuclear Medicine And Ultrasound,
BSMMU Campus Block, Dhaka, Bangladesh
(P-79) I-131 Meta-Iodobenzylguanidine and Tc99m Sestamibi Parathyroid SPECT Scintigraphy in Diagnosis of
Multiple Endocrine Neoplasia 2A Syndrome
Dr Jamilla Gomez, Nuclear Medicine, St Lukes Hospital, Quezon City, Philippines
(P-80) Myocardial Perfusion Imaging and Calcium Scoring as Coronary Artery Disease Predictors
Dr Jamilla Gomez, Nuclear Medicine, St Lukes Hospital, Quezon City, Philippines
(P-81) Comparison of Tc-99m Ethambutol Scintigraphy and Scoring System in Diagnosing Pediatric Tuberculosis
Dr Ivana Dewi Mulyanto, Department of Nuclear Medicine, Universitas Padjadjaran/RS Hasan Sadikin,
Bandung, Indonesia
(P-82) Clinical Utility of F-18 FDG PET/CT & Tc-99m MDP Bone Scintigraphy in Ewing's Sarcoma and Other
Sarcomaas
Dr Judy Nguyen, Nuclear Medicine, Stanford University Medical Center, Stanford, USA
(P-83) Castleman’s Disease on18FGD PET-CT
Dr Jamilla Gomez, Nuclear Medicine, St Lukes Hospital, Quezon City, Philippines
(P-84) Correlation Between Bone Scintigraphy and Tumour Markers in Patients with Breast Cancer
Dr Mohshi Um Mokaddema, Nuclear Medicine, Institute of Nuclear Medicine and Ultrasound, Dhaka, Bangladesh
(P-85) Impact of F-18 FDG PET/CT in Staging of Carcinoma Cervix
Dr Zaheer Chirag, Nuclear Medicine, BINO Cancer Hospital, Bahawalpur, Pakistan
(P-86) Clinical Implications of PSA Level & Gleason Score in Predicting Possible Metastatic Bone Disease in
Patients of Carcinoma Prostate
Dr Zaheer Chirag, Nuclear Medicine, BINO Cancer Hospital, Bahawalpur, Pakistan
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Day 3: WEDNESDAY, 30 November 2011 (cont’d)
(P-87) Role of FDG PET/CT in Diagnostic Evaluation of Carcinoma Urinary Bladder: Comparison with CT
Dr Dhritiman Chakraborty, Department of Nuclear and Experimental Medicine, IPGME & R, Kolkata, Kolkata, India
(P-88) Role of Tc99m MIBI Lower Limb Muscle Perfusion SPECT: In Diagnosis and Follow Up of Peripheral
Arterial Diseases (PAD)
Dr Rashid Rasheed, Nuclar Medicine, GINUM, Gujranwala, Pakistan
(P-89) Carotid Intima-Media Thickness (CIMT) as a Predictor of Hemodynamically Significant Coronary Artery
Disease (CAD) Detected by Myocardial Perfusion Imaging (MPI)
Dr Tapati Mandal, Nuclear Medicine, Institute Of Nuclear Medicine And Ultrasound, Dhaka, Bangladesh
(P-90) Hepatobiliary Scintigraphy in the Non-Invasive Assessment of Early Hepatic Dysfunction in Patients with
Risk Factor for Metabolic Syndrome
Dr Ajit Shinto, Nuclear Medicine and PET, KMCH, Coimbatore, India
(P-91) Tc 99m HIDA Diagnoses Early Hepatic Dysfunction in Type II Diabetics
Dr Ajit Shinto, Nuclear Medicine and PET, KMCH, Coimbatore, India
(P-92) Early and Delayed F-18 FDG PET in Assessment of Disease Activity in Tuberculosis
Dr Ajit Shinto, Nuclear Medicine and PET, KMCH, Coimbatore, India
(P-93) Vision of Nuclear Medicine in Bangladesh – A Road Map
Prof Mizanul Hasan, Nuclear Medicine, Institute Of Nuclear Medicine & Ultrasound, BSMMU, Dhaka, Bangladesh
(P-94) Technetium-99m-Sestamibi Scintigraphy on Patient with Nasopharingeal Carcinoma and Lympadenopati
Tuberculosa: A Case Report
Dr Yulia Kurniawati Burhanuddin, Nuclear Medicine, Hasan Sadikin Hospital, Bandung, Indonesia
(P-95) Evaluation of Low Grade Gliomas Using F-18 FDOPA and F-18 FDG PET/CT
Dr Abhinav Jaimini, Department of Clinical PET, Institute of Nuclear Medicine and Allied Sciences, Delhi, India
(P-96) Case Report: Tc-99m-Ethambuthol Uptake in Case of Leprosy
Dr Andika Hananto Gunawan, Department Of Nuclear Medicine, Hasan Sadikin Hospital / Univesitas Padjadjaran,
Bandung, Indonesia
(P-97) Role of Tc-99m Ethambutol Scintigraphy in Diagnosing Tuberculosis in Children with Scoring Systems as
Diagnostic Approach
Dr Alvita Dewi Siswoyo, Nuclear Medicine, Rs Dr. Hasan Sadikin, Bandung, Indonesia
(P-98) Role of Dobutamine Stress Myocardial Perfusion Imaging (DS MPI) for the Detection of Myocardial Viability
(MV) in Significantly Stenosed Coronary Artery Disease (CAD)
Dr Sarwat Ara Sultana Khandaker, Nuclear Medicine, Institute Of Nuclear Medicine & Ultrasound, Dhaka,
Bangladesh
(P-99) Optimization of SPECT MPI Using a Prototype Dynamic Heart Phantom
Dr Ourania Demetriadou, Nuclear Medicine, Limassol General Hospital, Limassol, Cyprus
(P-100) Outcome of Patients with Positive Exercise Test and Normal Exercise Myocardial Perfusion SPECT
A/Prof Faria Nasreen, Nuclear Medicine, Institute Of Nuclear Medicine & Ultrasound, Dhaka, Bangladesh
(P-101) Usefulness Of Dacryoscintigraphy in the Management of Patients with Epiphora
Dr Madhur Kumar Srivastava, Nuclear Medicine, Apollo Hospitals, Chennai, India
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Day 3: WEDNESDAY, 30 November 2011 (cont’d)
(P-102) Noninvasive Rest and Acetazolamide 99mtc-HM-PAO Brain Perfusion SPECT Imaging with One Day
Protocol Using SPECT/CT System
Dr Dang An Binh, Nuclear Medicine, Cho Ray Hospital, Ho Chi Minh, Vietnam
(P-103) Differentiating Benign and Malignant Lesions of Uterus by FDG and FES PET Imaging
Dr Raihan Hussain, Thyroid Division, Institute of Nuclear Medicine and Ultrasound, Dhaka , Bangladesh
(P-104) Illustration of a Single Anomalous Coronary Artery with Myocardial Ischemia by Fusion of N-13 Ammonia
PET/CT with CT Coronary Angiography – Case Report
Prof Bom Hee-Seung Henry, Nuclear Medicine, CNU Medical School, Hwasun, S. Korea
(P-105) Comparative Study of Exercise Tolerance Test (ETT) and SPECT-Myocardial Perfusion Imaging (MPI) in the
Diagnosis of Coronary Artery Disease in Bangladeshi Women
Dr Akhter Nahid, Nuclear Medicine, Centre For Nuclear Medicine & Ultrasound, Dinajpur, Dhaka, Bangladesh
(P-106) Radiation Exposure of Patients Undergoing Whole-Body Dual-Modality 18F-FDG PET/CT Examinations at
Choray Hospital – Vietnam
Dr Le Tran Tuan Kiet, Radiation Safety, Cho Ray Hospital, Ho Chi Minh, Vietnam
(P-107) The Role of 99mtc-MIBI Pinhole Scintigraphy in Preoperative Parathyroid Localization in Era of SPECT/CT
Dr Lucia Kaliska, Nuclear Nuclear Medicine, Institute Of Nuclear Medicine & Molecular Medicine, Banska Bystrica,
Slovakia
(P-108) Langerhans Cell Histiocytosis. Imaging Findings and Utility of FDG PET/CT in an Adult Patient with Multi-
Organ Involvement
Dr Xie Wanying, Nuclear Medicine, Singapore General Hospital, Singapore
(P-109) Juxtapapillary Dieulafoy Lesion: An Obscure Case of G.I. Bleeding Localized Using Tc-99m RBC
Scintigraphy
Dr Millicent Grace De Guzman, Nuclear Medicine, University of Santo Tomas Hospital, Manila, Philippines
(P-110) Utility of Delayed Imaging in Evaluating Common Bile Duct Obstruction with Tc-99m Mebrofenin
Hepatobiliary Scanning
Dr Nand Relan, Radiology, Stony Brook University Medical Center, Stony Brook, USA
(P-111) Role of 18F-Fluoro-Deoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging
(18F-FDG PET/CT) for Preoperative Axillary Staging in Primary Breast Cancer: A Prospective Analysis
Dr Ankur Pruthi, Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre,
New Delhi, India
(P-112) Role of FDG in Primary Lesion Identification (A Preliminary Result)
Dr Hendra Budiawan, Nuclear Medicine, MRCCC - Siloam Hospitals, Jakarta Indonesia
(P-113) PET/CT and Contrast Enhanced CT in the Detection of Malignant Lesions: A Prospective Study
Dr Susan Gironella-Camomot, Nuclear Medicine, Cagayan de Oro Medical Center, Cagayan de Oro City,
Philippines
1600 – 1630 SCIENTIFIC SESSION 8: EDUCATION & TRAINING, MOLECULAR IMAGING Ben Thanh Hall, Level 1
Session Chairpersons:
1. Prof Lee Jae-Tae, Nuclear Medicine, Kyungpook Natioanl University Hospital, Daegu, Korea
2. Prof Jun Hatazawa, Japan
1600 – 1630
(O-52)
Training Nuclear Medicine Physicians Foundation and Ideal Model
Prof Abdelhamid Elgazzar, Nuclear Medicine & PET, Medicine University of Kuwait, Kuwait
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Day 3: WEDNESDAY, 30 November 2011 (cont’d)
1630 – 1710 ORAL PRESENTATIONS (ARCCNM) Ben Thanh Hall, Level 1
1630 – 1640
(O-53)
Detection of Activated Microglia with Translocator Protein (18 Kda) Ligand, [18F]FEPPA PET
Prof Hiroshi Toyama, Radiology, Fujita Health University, Toyoake, Japan
1640 – 1650
(O-54)
FDG Uptake, Glucose Transporter Type-1 and KI-67 Expressions
Dr Xuan Canh Nguyen, Unit Of Pet/Ct And Cyclotron, Cho Ray Hospital, Ho Chi Minh, Vietnam
1650 – 1700
(O-55)
Early Response Assessment in Gastrointestinal Stromal Tumors with FDG PET Scan 24 Hours after a
Single Dose of Imatinib
Dr Ajit Shinto, Nuclear Medicine and PET, KMCH, Coimbatore, India
1710 – 1800 ARCCNM NATIONAL DELEGATES' ASSEMBLY To Be Advised
1745 – 1900 WARMTH MEMBERS' ASSEMBLY
ALL MEMBERS OF WARMTH TO ATTEND THE MEETING Ben Thanh Hall, Level 1
1930 – 2300 DINNER & 10 YEARS OF ARCCNM CELEBRATION Grand Mekong Ballroom,Level 1
2300 END OF DAY 3
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Day 4: THURSDAY, 1 December 2011
0800 – 1030 SCIENTIFIC SESSION 9: DOSIMETRY, MOLECULAR IMAGING, GENERAL Ben Thanh Hall, Level 1
Session Chairpersons:
1. Prof Lee Myung Chul, Nuclear Medicine, Seoul National University, Seoul, Korea
2. Dr Pankaj Dougall, Nuclear Medicine Services, Nuclear Medicine And PET-CT, Max Super Speciality
Hospitals, New Delhi, India
0800 – 0825
(O-56)
Usefulness of SPECT/CT for Radionuclide Therapy
Dr Cornelis Hoefnagel, Division of Diagnostic Oncology, The Netherlands Cancer Institute, The Netherlands
0825 – 0850
(O-57)
The Utility of PET in Intensity Modulated Radiotherapy Planning
Dr Lee Sze Ting, Centre For PET, Austin Hospital & Ludwig Institute For Cancer Research, Heidelberg, Australia
0850 – 0910
(O-58)
Prognostication in Radionuclide Therapy
Prof Sobhan Vinjamuri, Nuclear Medicine Dept, Royal Liverpool University Hospital, Liverpool, UK
0910 – 0930
(O-59)
The 3-D Dosimetry in Radionuclide Therapy Based on 4D SPECT/CT Acquisition
Prof Kalevi Kairemo, Molecular Radiotherapy & Nuclear Medicine, International Comprehensive Cancer Center
Docrates, Helsinki, Finland
0930 – 0950
(O-60)
Dosimetry in Solid Tumours – Does it have Any Use
Prof John Buscombe, Nuclear Medicine, Royal Free Hospital, Cambridge, UK
0950 – 1010
(O-61)
Current Knowledge of FET use in PET
Dr Malkowski Bogdan, Department of Nuclear Medicine, Oncology Centre, Bydgoszcz, Poland
1010 – 1030
(O-62)
The Tracer Principle: From De Hevesy's Cup of Tea to the Secret Services?
Prof Alan Perkins, Radiological And Imaging Sciences, Nottingham University Hospitals,
Nottingham, United Kingdom
1030 – 1100 COFFEE / TEA / TRADE EXHIBITION Ben Thanh Hall FoyerPre-Function Area, Level 1
POSTER PRESENTATIONS: MISCELLANEOUS Ben Thanh Hall FoyerPre-Function Area, Level 1
Session Coordinators:
1. Ms Dang Truong Ka My, PET-CT and Cyclotron, Cho Ray Hospital, Ho Chi Minh, Vietnam
2. Dr Nguyen Thi Thuy Hang, Vietnam
(P-114) Plasma Therapy: A New Era of Therapeutic Techniques
Dr Tanvir Ahmed Biman, Scintigraphy Division, Nuclear Medicine, Institute of Nuclear Medicine & Ultrasound,
Dhaka, Bangladesh
(P-115) Early Outcome of Chemotherapy in Lymphoma Patients Using Tc-99m Tetrofosmin Scintigraphy
Dr Muhammad Asif Rafique, Nuclear Medicine, Nuclear Medicine, Oncology And Radiotherapy Institute (NORI),
Islamabad, Pakistan
(P-116) Preparation of In-111 Oxine for Labeling of Stem Cell
Prof Ali Sattari, Nuclear Medicine, Agriculture And Medicine Research School, Karadj, Iran
(P-117) Sentinel Lymph Node Biopsy In Malignant Melanoma – Role of Lymphoscintigraphy in the Detection of
Unpredictable Lymphatic Drainage
Dr Zamfirescu Anca, Metabolic Radiotherapy,Bucharest Oncology Institute, Bucharest, Romania
(P-118) Dual-Phase Tc99m-MIBI Scinitigraphy in Lymphoma as a Predictor of Response to Chemotherapy
Dr Zaheer Chirag, Nuclear Medicine, BINO Cancer Hospital, Bahawalpur Pakistan
(P-119) Review of Utilization of Surveillance Scans in Lymphoma Patients – A Pilot Study
Dr Judy Nguyen, Nuclear Medicine, Stanford University Medical Center, Stanford, USA
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Day 4: THURSDAY, 1 December 2011 (Cont’d)
1100 –1245 SCIENTIFIC SESSION 10:BREAST CANCER, LYMPHOMA, RADIOIMMUNOTHERAPY (RIT) Ben Thanh Hall, Level 1
Session Chairpersons
1. Prof Hiroshi Toyama, Radiology, Fujita Health University, Toyoake, Japan
2. Dr Felix Sundram, Nuclear Medicine, Wijaya International and Sime Darby Medical Centres, Kuala
Lumpur, Malaysia
1100 –1130
(O-63)
IART in Breast Cancer
Prof Giovanni Paganelli, Divisione Di Medicina Nucleare, IEO Istituto Europeo Di Oncologia, Milano, Italy
1130 – 1150
(O-64)
Positron Emission Tomography in Breast Cancer
Dr Patricia Bernal Trujillo, Nuclear Medicine , Fundacion Santa Fe B Ogota, Colombia
1130 – 1210
(O-65)
Radioimmuno-Scintigraphy and Radioimmuno-Therapy. A State of the Art
Prof Izak Garty, Nuclear Medicine, Haemek Medical Centre, Afula, Israel
1210 – 1230
(O-66)
Radioimmunotherapy of Non-Hodgkin Lymphoma with 131I-Rituximab
Prof Harvey Turner, University Of Western Australia, Fremantle Hospital, Australia
1230 – 1245
(O-67)
Use of PET to Monitor the Results of I-131 CHT25 RIT
Dr Ewa Nowosinska, Nuclear Medicine Department, Royal Free Hospital, London, UK
1245 – 1315 ORAL PRESENTATIONS Ben Thanh Hall, Level 1
1245 – 1255
(O-68)
Potential Use of 177Lu In Radioimmunotherapy as Targeting Tracers on Monoclonal Antibodies
Dr Choi Sun-Ju, Radioisotope Research Division, Korea Atomic Energy Research Institute, Daejeon, Korea
1255 – 1305
(O-69)
Effect of Molecular Imaging on Evaluation of the Therapeutic Efficacy of VEGFR2 Blocking Antibody in a
Sodium-Iodide Symporter Gene Expressed Tumor Model
Dr Cheong Su-Jin, Nuclear Medicine, Chonbuk National University Medical School and Hospital, Jeonju, Korea
1305 – 1315
(O-70)
Diagnostic Efficacy of Scintimammography for Detection of Malignant Tissue in the Breast Performed with
Tc-99m MDP and Tc-99m Sestamibi
Prof Birendra Kishore Das, Nuclear Medicine, Utkal Institute of Nuclear Medicine, Bhubaneswar, India
1315 – 1400 LUNCH / TRADE EXHIBITION
1400 – 1530 SCIENTIFIC SESSION 11: RADIONUCLIDE THERAPY & QUALITY OF LIFE Ben Thanh Hall, Level 1
Session Chairpersons:
1. Prof Irene Virgolini, Nuclear Medicine & PET, University Of Innsbruck, Innsbruck, Austria
2. Prof Abdelhamid Elgazzar, Nuclear Medicine & PET, Faculty of Medicine University of Kuwait, Kuwait
1400 – 1425
(O-71)
The Value of Life and the Concept of QOL: A Critical Examination of the Basic Principles for Clinical
Measurement of QOL
Dr Remigius Orjiukwu, Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria
1425 – 1450
(O-72)
QOL from A Doctor’s Perspective : Review of Actual Clinical Data
Prof Irene Virgolini, Nuclear Medicine & PET, University Of Innsbruck, Innsbruck, Austria
1450 – 1515
(O-73)
QOL from A Patient Perspective
Mr William Claxton, CNETS, Singapore
1515 – 1525 COFFEE / TEA / TRADE EXHIBITION Ben Thanh Hall FoyerPre-Function Area, Level 1
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1525 – 1550 SCIENTIFIC SESSION 12:
RADIONUCLIDE THERAPY – FUTURE PERSPECTIVES & CLOSING CEREMONY Ben Thanh Hall, Level 1
Session Chairpersons:
1. Prof Ajit Kumar Padhy, Nuclear Medicine, Singapore General Hospital, Singapore
(President-WARMTH)
2. Prof Henry Bom Hee-Seung, Nuclear Medicine, CNU Medical School, Hwasun, South Korea
1525 – 1550
(O-74)
THERANOSTICS: From Molecular Imaging Using PET/CT with Ga-68 Labeled Tracers to Personalized
Therapy
Prof Richard Baum, Department of Nuclear Medicine, Center For PET/CT, Bad Berka, Germany
1550 – 1700 CLOSING CEREMONY Ben Thanh Hall, Level 1
1550 – 1600 AWARDS:
 BEST ORAL PRESENTATION – 3 PRIZES
 BEST POSTER – 3 PRIZES
1600 – 1607 NEXT CONFERENCE
 3rd International Symposium on Radiopharmaceutical Therapy (ISRT-2012), Levi, Finland
Prof Kalevi Kaieremo (Finland)
1607 – 1615 5th International Conference on Radiopharmaceutical Therapy (ICRT-2013)
(Selection of Venue)
1615 – 1620 Closing Remarks
Prof Henry Bom (ARCCNM)
1620 – 1625 Closing Remarks
Dr Nguyễn Trường Sơn (Cho Ray Hospital)   
1625 – 1630 Vote of Thanks
Dr Nguyễn Xuân Cảnh (Local Organizing Secretary) 
1630 – 1700 Highlights & Closing Remarks
Prof Ajit Kumar Padhy, President, WARMTH
1710 SHUTTLE TRANSFER TO OENOPHILOUS DINNER
1730 – 2300 ENTERTAINMENT & OENOPHILOUS DINNER
2300 END OF DAY 4
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Day 5: FRIDAY, 2 December 2011
0730 Departure to Cu Chi Tunnels for Sight-Seeing Tour
0930 –1130 Cu Chi Tunnel Tour
1130 –1230 Ho Chi Minh Memorial
1230 –1500 LUNCH
1600 Return to Hotel
Last Evening in Ho Chi Minh City
All Participants Will Have A Free Evening. This Evening’s Dinner Is Not Included In The Lump-Sum. Participants
Are Free To Go Out For Sight Seeing In The City With Friends Or Do Shopping; And Later For A Change Should
Try Out Some Of The Delicious Vietnamese Cuisine For Dinner.
Day 6: SATURDAY, 3 December 2011
Post-Congress Tour of Siem Reap, Cambodia
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Abstracts of Poster Presentations 
(Benign and Malignant  
Thyroid Disease)
P-001
Is 99Tcm Thyroid Planar Imaging Suit-
able for Evaluating Residue Thyroid 
after Thyroidectomy: Comparing with 
I131 Scan after Radioiodine Therapy
S. Wu
Nuclear	Medicine,	Xinhua	Hospital,	Shanghai,	China
Objective: In China,99Tcm thyroid planar imaging 
was the most popular way to evaluate the residue 
thyroid after thyroidectomy. This study wanted to 
observe the difference between 99Tcm thyroid scan 
and I131 scan after radioiodine therapy in thyroid 
cancer.
Materials and Methods: Total 103 histologically 
proven papillary thyroid cancer (PTC) patients(pts) in 
recent 2-year were collected into the study(42 male,61 
female, age 44.5±14.4y). The images were respectively 
interpreted by 2 nuclear medicine doctors with a 5-point 
method, unknown the patients information. The data 
were analyzed by Logistic Regression.
Results: 34/103 (33%) pts had the same score in two 
scan, especially the high score (≥3).But it was been up 
regulated in I131 scan in other 69(67%) pts. And most of 
the pts who had small score(0-1) in 99Tcm scan would 
be higher in I131 whole-body scan.9 pts even showed 
lung and lymph nodes metastases in I131 scan, which 
were confirmed by CT and more than one year follow-
up. The giving doses (OR=1.135,95% CI 1.026-1.255) and 
the level of blood triiodothyronine (T3) (OR=0.001,95% 
CI 0.0-0.206) had relationship with thyroid stimulating 
hormone.
Conclusion: 99Tcm thyroid planar imaging may not suitable 
for evaluating residue thyroid compared with I131 scan.
P-002
Tc-99m MIBI Scintigraphy for the 
follow up Evaluation of Differenti-
ated Thyroid Carcinoma Patients after 
Therapy
R. Yudistiro, B. Hidayat, H. Kartamihardja, 
J. S. Masjur
Nuclear	Medicine,	 Universitas	 Padjadjaran,	 Bandung,	
Indonesia
Introduction:  Long-term follow-up should be 
performed in  post - tota l  thyroidectomy and 
radiothyroablation with NaI-131 Differentiated 
Thyroid Carcinoma (DTC) patients. Thyroglobulin 
serum (Tg-off) and Thyroglobulin-antigen antibody 
(AbTg) level in stimulating TSH should be measured 
in follow-up assessment every 6-12 months. NaI-131 
scintigraphy is done to detect location of remnant 
thyroid and/or metastases. Nevertheless, NaI-
131 scintigraphy has some disadvantages, such 
as patient’s discomforts and stunning effect. Tc-
99m MIBI is already common used for myocardial 
perfusion scan and recently is used for tumor 
seeking agent. Some studies showed varied results 
for the usage of Tc-99m MIBI scintigraphy in post-
therapy DTC patients follow-up, so the advantages 
of Tc-99m MIBI scintigraphy is still controversy. 
Aims: To evaluate diagnostic value of Tc-99m MIBI 
and NaI-131 scintigraphy for post-therapy DTC 
follow-up patients' using Tg-off level as gold standard.
Materials and Methods: In this study we performed 
diagnostic test to evaluate sensitivity, specificity, positive 
predictive value (PPV), negative predictive value (NPV), 
and accuracy of Tc-99m MIBI and NaI-131 scintigraphy 
using Tg-off level as gold standard. We evaluated 56 
post-therapy DTC patients while doing follow-up 
assessment after therapy. Tc-99m MIBI scintigraphy 
was done when subjects were in thyroxin suppression 
therapy. Withdrawal of thyroxin suppression therapy 
was done at 3 – 4 weeks before follow-up assessment. Tg-
off, AbTg, TSH level and administration of NaI-131 orally 
was done at follow-up assessment. NaI-131 scintigraphy 
was done at 24 and 48 hours after the administration of 
NaI-131.
Results: Tc-99m MIBI is more sensitive compared with 
NaI-131 with sensitivity value is 86.7% versus 80%. 
NaI-131 is more specific compared with Tc-99m MIBI 
with specificity value is 87.8% versus 82.9. PPV, NPV, 
and accuracy for Tc-99m MIBI scintigraphy are 65%, 
94.4%, and 83.9%. PPV, NPV, and accuracy for NaI-131 
scintigraphy are 70.6%, 92.3%, and 85.7%. Analytical 
statistics using Chi Square Test (95% Confidence 
Interval) showed there is significant difference 
between Tc-99m MIBI and NaI-131 scintigraphy 
(P<0.001).
Discussion: There is significant difference in the 
diagnostic value between Tc-99m MIBI and NaI-131 
scintigraphy for post-therapy DTC patients' follow-
up. Tc-99m MIBI is sensitive but less specific for 
post-therapy DTC patients' follow-up. This study 
showed that Tc-99m MIBI scintrigraphy is also able 
to detect more positive results in patients with AbTg 
positive.
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P-003
Effect of I-131 Large Dose Thyroid 
Carcinoma Therapy on Submandibular and 
Parotid Glands: Quantitative Analysis of 
Salivary Excretion Pre and Post Therapy
O. P. Sinha, M. Mayank, R. Tiwari, S. Rachch, 
M. K. Soni, V. Bhatt
Nuclear	Medicine,	Gujarat	Cancer	 and	Research	 Institute,	
Ahmadabad,	India
Introduction: Radioiodine was first introduced in 1940 as an 
oncologic therapeutic agent after more than 70 years I-131 
has become the agent of choice and now available in many 
countries. Sialadenitis is direct result of radiation injury from 
iodine uptake, which can be seen on a post- therapeutic whole 
body scan. The complication can be divided into acute and 
chronic radiation Sialadenitis. Damage to salivary gland can be 
quantitated through technetium pertechnetate scintigraphy. 
This study shows large reduction function of salivary gland.
Patients: Total of 190 patients was included in this study. 
Group A- 80 pts. Got 30-80mci I-131. Group B- 90 patients 
got 100mci. Group C- got 120-200mci of I-131.
Materials and Methods: Technetium procured from 
BRIT, Mumbai. Pre and 1-month post therapy 99Tc0- 
scan done on all patients with GE Infinia gamma camera.
Results: We quantified the salivary excretion pre and 
1-month post- radioiodine therapy. In all patients pre- 
therapy salivary excretion was 50-70% but after therapy 
group A, B and C showed different results. Group A- post 
therapy excretion was 25-45%, group B-20-30%, group C 
10-20%. These results clearly shows that when the I-131 
dose increases salivary excretion decreases. Sequentially, 
keeping a piece of lemon in the mouth for 48hrs reduced 
the dose to salivary gland and excretion also improved.
Conclusion: Sialadenitis can be prevented with lower activity 
of prescribed I-131, good hydration, use of sialogogues and 
lemon juice. Low risk patient who require remnant ablation 
with I-131 should be given the lowest dose of I-131.
P-004
Serum Thyroglobulin Level Alone Is 
Not Enough To Monitor Persistence or 
Recurrence Disease of Differentiated 
Thyroid Carcinoma
Aisyah Ellianti
Faculty	 of	Medicine	Andalas	University,	Dr.	M.	Djamil	
Hospital,	Padang,	Indonesia
To monitor persistence or recurrence of disease and to 
evaluate the effectiveness of treatment for differentiated 
thyroid cancer (DTC), serum thyroglobulin (Tg) is 
widely accepted as a tumor marker. However, Tg level 
can be misleading in certain instances in which levels 
are low but have recurrence. The aim of this study is to 
prove that Tg test alone is not conclusive in monitoring 
persistence or recurrence of disease in patients with DTC. 
A retrospective study was conducted for 40 patients, 
36 females and four males, who received I-131 therapy 
during a 2- year period, 2008-2010, and of an age group 
of 19 to 78 years. During the follow-up, Tg and anti-Tg 
antibody (TgAb) were examined after four weeks period 
of levothyroxine hormone withdrawal. Additionally, 
bone scintigraphy was performed. Tg level, >2 ng/mL, 
was regarded as a persistence or recurrence disease, with 
Tsh levels of >30 uIU/mL.
Serum thyroglobulin >2ng/mL and negative TgAb were 
discovered in 6/40 patients, comprising 15% of the total 
number. Two out of those 6 patients had shown a high 
uptake at sternum and caput of os.femur dextra with bone 
scintigraphy; however, negative uptake of I-131 on whole 
body scan after therapy. Tg ≤ 2ng/mL and TgAb negative 
were discovered in 34/40 patients, comprising 85% of the 
total number. Four out of the 34 patients had shown an 
abnormal uptake in the bone scan. The first had a diffuse 
uptake at os.parietal bilateral and sacro-iliac joint dextra 
on bone scan; however, none was discovered at these sites 
after therapy with I-131 under whole body scan and very 
light uptake level at thyroid bed. The second patient had 
also an abnormal uptake at os.costa V dextra with bone 
scintigraphy; however did not show after therapy with 
I-131 under whole body scan. Moreover, a follow-up, 
six months later, had shown no uptake at that site. The 
remaining two patients had concurrent results of bone 
scintigraphy and I-131 whole body scan after therapy. From 
the above, we conclude that serum thyroglobulin test cannot 
be considered as a single indicator in monitoring thyroid 
cancer; furthermore, TgAb examination and imaging tests, 
such as bone scintigraphy, should be included to improve 
diagnostic value in identifying persistence or recurrence 
disease. All test results should be treated on a case-by-case 
basis and not as a general guide, where test results cut-off 
point confirms variation in values.
P-005
Pattern of Metastases in Well-differen-
tiated Thyroid Microcarcinoma
S. Fithriany, B. Hidayat, B. Darmawan, 
A. H. Kartamihardja, J. Masjur
Department	 of	Nuclear	Medicine,	Hasan	Sadikin	Hospital	
Bandung,	Indonesia
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Surgery (lobectomy, near-total thyroidectomy) is 
the primary treatment of well-differentiated thyroid 
carcinoma (DTC). According to ATA recommendation 
2009, thyroid lobectomy alone may be a sufficient 
treatment for the small nodule (< 1cm), low- risk, 
unifocal, intrathyroidal carcinomas in the absence of 
prior head and neck irradiation or radiologically or 
clinically involved cervical nodal metastases. DTC 
may spread to lung, bone, liver and lymph node, but 
metastases from differentiated thyroid microcarcinoma 
is uncommon. 
We had five patients (4 PTC, 1 FTC) who presented with 
metastases in various organs as the first sign of DTC, 
without visible or palpable lump in the thyroid gland. 
The presenting symptoms of 4 PTC patient were cervical 
lymphadenopathy due to suspected mycobacterium 
tuberculosis infection, blurred vision due to intracranial 
mass, fracture compression at lumbar bone with multiple 
vertebrae lumbar metastases based on anatomical 
imaging, and mass in parieto-occipital dextra. While the 
FTC patient had fracture compression at lumbar bone 
with multiple vertebrae lumbar metastases based on 
anatomical imaging as presenting symptoms. During 
work-up period, there is no primary malignancy. All 
patients underwent to surgery and the histopathological 
results showed metastases from thyroid carcinoma. 
After that, patients referred to total thyroidectomy, and 
the only abnormality macroscopic finding was small 
nodule (<1 cm). Whole body scintigraphy after RAI-131in 
one PTC patient showed more extensive metastases at 
frontal, humerus, pelvis and femoral bones.
Discussion: Histopathology is the gold standard to 
differentiate type of DTC. Each type of DTC has its own 
metastases pattern. From these patterns, a clinician may 
decide management that influence patient’s prognosis.
Conclusion: The possibility of thyroid carcinoma must 
be considered, from patients with suspected metastases 
as the presenting symptoms although no lump is 
palpable in the thyroid gland.
P-006
Outcome o f  Pregnancy  a f ter 
Radioactive Iodine Treatment 
Y. Dessie, B. Hidayat, B. Darmawan
Department	 of	 Nuclear	Medicine,	 School	 of	Medicine	
Universitas	Padjajaran,	Dr.	Hasan	Sadikin	Hospital	West-Java	
Bandung,	Indonesia
Radiothyroablation I-131 (RAI) is an effective 
treatment for high-uptake hyperthyroidism and as 
an adjuvant treatment for post-total thyroidectomy 
for well-differentiated thyroid carcinoma (DTC). The 
administration of 131-I is strictly contraindicated in 
pregnancy. The exposure from RAI-131 is a risk on fetal 
growth. The goal of this study was to investigate the 
outcome of pregnancy in patients with differentiated 
thyroid carcinoma and hyperthyroidism who became 
pregnant after RAI.
Materials and Methods: Retrospective study were done 
with the data collected based on medical records from 
our hospital between January 2004 until December 2010. 
RAI activity doses for hyperthyroidism between 4–12 
mCi while for DTC between 80-150 mCi.
Results: RAI was delivered to 1064 hyperthyroidism and 
127 DTC female subjects. A total of 12 pregnant subjects (4 
hyperthyroidism, 8 DTC) were recorded during this study 
period. Five of these subjects (1 hyperthyroidism, 4 DTC) 
got pregnant within 6 months after the last administration 
of I-131. One of them had blighted ovum. This subject had 
been pregnant two weeks after receiving 100 mCi NaI-
131 for thyroid ablation. The other eleven subjects had 
normal pregnancy, nine of them had delivered healthy 
term babies, and two of them are still in gravid.
Discussion: During the first and the second trimester 
of gestational age, the embryo undergoes rapid growth 
and development. At this point in time, embryonic cells 
are still able to differentiate into many types of cell. This 
period is extremely vulnerable for radiation exposure.
Conclusion: We conclude that radioiodine did not have 
any deleterious effect on fetus growth and development, 
that is if pregnancies occurred at least after six months 
exposure from RAI-131 treatment. 
P-007
Radioactive Iodine Ablation in Young 
Adults with Differentiated Thyroid 
Carcinoma
Y. T. Jelani, B. Darmawan, B. Hidayat, 
A. H. Kartamihardja, J. S. Masjur
University	of	Padjadjaran,	Bandung,	Indonesia
Introduction: The prevalence of thyroid carcinoma in 
young adults is about 10% of thyroid malignancy cases. 
We reported our experience in using radioactive iodine 
(NaI-131) ablation for young adults with post-total 
thyroidectomy differentiated thyroid carcinoma.
Materials and Methods: A retrospective study was 
conducted in young adults subjects with differentiated 
thyroid carcinoma who has undergone post-total 
thyroidectomy and followed by radioiodine ablation 
therapy. Data was collected from 25 medical records 
in our department from 1998 to 2010. Histological and 
laboratory findings (serum TSHs, thyroglobulin/Tg and 
Anti-Thyroglobulin Antibody/ATA levels) were noted 
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until at least six months after ablation. Only 15 patients 
were eligible. Complete response after ablation was 
defined if Tg serum level < 3 ng/ml, with TSHs serum 
level > 30 µIU/ml and no detected ATA level; outside 
this level was defined as residual disease.
Results: Of 15 subjects (12 females and 3 males, aged 13-
21 years.), 9 subjects had papillary thyroid carcinoma / 
PTC (60%) and 6 subjects had follicular thyroid carcinoma 
/ FTC (40%). Metastases were found in 5 subjects (33.3%) 
with loco-regional lymphatic metastases, 3 subjects (20%) 
with pulmonary metastases, one subject (6.6%) with bone 
metastases and one subject (6.6%) with metastases in soft 
tissue. The first ablation I-131 dose was given between 
80-100 mCi. Next I-131 was given after 6- 12 months or 
more, if needed, by increasing the dose to 150 mCi. Three 
subjects (1 PTC, 2 FTC) had complete response after first 
ablation, one subject (1 PTC) after second dose, and one 
subject (1 PTC) after third dose. Four of five subjects had 
thyroglobulin serum level < 10 ng/dl. Eighteen months 
after radioiodine ablation, 10 subjects (66.6%) were still 
positive for residual functioning thyroid tissue with 
thyroglobulin serum levels more than 10 ng/dl.
Discussion: The accepted management of differentiated 
thyroid carcinoma is total thyroidectomy, followed by 
radioactive iodine (I-131) ablation and suppressive doses 
of thyroid hormone. Complete response was found in 3 
subjects after six months post- radioactive iodine ablation. 
Other studies used thyroglobulin serum level < 3 ng/
dl as the criteria of good response to therapy. Based on 
these criteria, good response was found in four patients 
with thyroglobulin serum level < 3 ng/dl. Papillary 
thyroid carcinoma in young adults has a favorable 
prognosis. The favorable prognosis is associated with 
lymphocytic infiltration, as an anticancer reaction during 
the immunologic activity. Young adults usually have more 
advanced tumors, with local and distant metastases and 
have higher recurrence rates. Children under 10 years of 
age have very high mortality rates. In conclusion, it seems 
that age, histopathology classification, and distant nodal 
metastases are important factors for non-responsiveness 
of well-differentiated thyroid carcinoma in young adults 
to radioactive iodine ablation.
P-008
Applications of Nuclear Medicine 
Techniques in Diagnosis and Treatment 
of Differentiated Thyroid Carcinoma: 
Results in Vietnam
Phan Sy An
Nuclear	Medicine	and	Oncology	Centre,	Bach	Mai	Hospital,	
Hanoi,	Vietnam
Differentiated thyroid carcinoma (DTC) is a common 
disease in Vietnam. Nuclear medicine has been used 
for diagnose thyroid diseases and especially for thyroid 
cancer. However, the application of multimodalities 
(including radioiodine) in treatment of DTC has just been 
practiced since 1994. Till now, there are 8 Departments 
of Nuclear Medicine in Vietnam, where the treatment 
and follow up of thousands of DTC has been underwent 
in routine. This meta-analysis took data from the local 
published reports about this topic. The author has 
revealed some conclusions as follow:
• NM technique in the diagnosis and treatment of 
DTC has high benefit. This method is safe and cost-
effective. 
• There are more and more NM departments in 
Vietnam has sufficient human resources, conditions 
and equipments to expand the utilities of NM 
techniques in diagnosis and treatment of DTC.
• From their own studies, Vietnamese NM physicians 
have confirmed specific and scientific knowledge in 
DTC management:
a. Thyroid and whole body scintigraphy play an 
important role in diagnosis, monitoring and 
evaluation of DTC treatment outcomes.
b. Ablation of postoperative remnant thyroid 
tissue in DTC is the first essential step in DTC 
treatment. Estimating doses (from 30-100 mCi) 
depends on several parameters individually. 
The results depend on many factors but the most 
important ones are the volume of thyroid tissue 
left after surgery, histopathology type (papillary 
response better than the follicular ones)…Almost 
department gained complete response: nearly 
80%, partial response: 10%, no response: <10%.
c.  Majority of our patients coming to physicians 
had metastases (lymph nodes, lungs, bones..) or 
recurrent. So they have been treated with multiple 
doses (between 2 - 5 times) to gain better treatment 
outcomes. Maximum dose was 512,2 +- 100,2 mCi. 
d. Clinical examinations and necessary laboratory 
tests are essential in diagnosis, evaluation and 
follow up. Determination of serum Tg and Anti-
Tg levels, neck and whole body scintigraphy with 
I-131, bone scintigraphy with MDP-Tc-99m, lung 
perfusion with MIBI-Tc-99m, brain scintigraphy 
are very important.
e.  PET / CT have been used for DTC management in 
Vietnam. Its benefit in patients having difficulties 
in detecting distant metastases by SPECT, PET / 
CT with FDG has discovered more than 65.5% 
patients with metastases and/or recurrence but 
previously negative with I-131 SPECT. 
f.  Tg, Anti Tg is being proved here. Results from 
some studies also showed that determination 
of both Tg and Anti Tg serum concentrations 
is very important, because 38.5% of patients 
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clinically diagnosed as DTC having the positive 
scintigraphy (thyroid tissue remaining after 
thyroidectomy), but Tg levels were <10 ng/ml. 
The reason for this phenomenon is the higher Anti 
Tg levels (> 16,85 +- 3,96 IU/ml).
g.  Some studies showed a discordance between 
the serum Tg (Tg ≤ 10ng/ml) and Anti Tg 
concentration (≤ 50 UI / ml) but a positive I-131 
whole body scintigraphy (9.16% of 1037 DTC 
patients in Cho Ray Hospital). This issue need 
further study to answer a reason.
P-009
Differentiated Thyroid Cancer 
Ablation: 5 Years Experience in 
Limassol General Hospital
O. Demetriadou, D. Kaolis, K. Hatjitoffi, 
N. Fasouliotis, A. Panayi, S. Kounma
Department	of	Nuclear	Medicine,	Limassol	General	Hospital,	
Limassol,	Cyprus
Introduction: The use of I131 in the treatment of 
patients with differentiated thyroid cancer has been 
well established in the past years. Thyroid cancer 
patients are given an ablation dose to eliminate the 
residual thyroid tissue after operation. The use of 131-I 
whole-body imaging before 131-I therapy, and whether 
“stunning” of the thyroid remnant occurs, remains under 
discussion. Therefore, nowadays different protocols of 
ablation therapy are in use in many centers: Ablation 
with standard dose without pre-therapy scan and or 
Pre-Therapy Scan and selection of the dose according to 
the results and or after dosimetric calculations.
Materials and Methods: Between January 2006 and June 
2011 we examined 127 patients, 99 women- mean age 
48.1. y (between 19-75 years) and 28 men-mean age 49.3 
y. (between 30-74) with differentiated thyroid cancer 
(Papillary Ca, Follicular Ca and Papillary Ca- follicular 
variant) after operation. These patients are followed up 
according to the following protocol: Initial diagnostic 
WB and static neck scan was performed 3-4 weeks after 
total thyroidectomy (TSH and Thyroglobuline levels 
done on the day of I131 administration), 24 hours after 
administration of 2.8 mCi I131. Ablation with doses 
between 28 mCi and 150 mCi was performed one week 
after. Patients, who were administered doses higher than 
28 mCi, were admitted in a dedicated room in Nicosia 
General Hospital and had post-ablation scan one week 
later. Follow up scans were performed between 8 months 
and one year, 4 years and 9 years post operation. Patients 
were 3-4 weeks on preparation (off Thyroxin). For the WB 
imaging a double-headed γ-camera Fillips Forte fitted 
with high energy collimators, matrix 256×1024, speed 5 
cm/min, energy 364 KeV with 20% window was used. 
Static anterior neck image was imaged with matrix 256 
for 5 minutes.
Results: A total of 82 patients out of 127 were followed-
up. 46 patients were given 28 mCi, 28 p. between 
100-120 mCi and 8 p. 140-150 mCi. The doses given 
were empirical taking into consideration the presence 
or absence of thyroid residua, lymph node or distant 
metastases on I131 WB diagnostic scan and the thyroid 
cancer risk (mentioned in the Textbook of Nuclear 
Medicine of Michael Wilson). 8 patients had abnormal 
first follow-up scan, 6 had minimal residua and 2 had 
lymph nodes.
Conclusion: We have demonstrated a relatively uniform 
ablation rate of 90.2% using empirical single doses of 
Iodine 131 ranging between 28-150 mCi. We have been 
taking into consideration the thyroid cancer risk, the 
results of the biopsy of the tumor and the presence or 
absence of thyroid residua or metastases on I131 WB 
diagnostic scans. We believe that the combination of 
the above factors (thyroid cancer risk and presence or 
absence of residua or mets) for the decision of the I131 
ablative dose to be used post thyroidectomy in patients 
with differentiated thyroid cancer is more easier than 
the complicated method using calculations (uptake and 
volume of thyroid residua) is cheaper as almost the half 
of the patients don’t need hospitalization and is having 
comparable results. The stunning effect was not observed 
and we believe that this is due to the use of low diagnostic 
doses and due to the short interval between diagnostic 
scan and administration of ablative doses.
P-010
Efficiency Predictive Factors of 
Radioiodine Ablation in Differentiated 
Thyroid Cancer
K. Chatti, G. Mohsen, B. Abir, S. Raja, N. Manel, 
K. Tarek, B. F. Maja, E. Habib
Department	of	Nuclear	Medicine,	Sahloul	University	Hospital,	
Sousse,	Tunisia
Introduction: Iodine-131 is often used in the management 
of Differentiated Thyroid Carcinoma (DTC). The aim 
of this paper is to establish the predictive value of 
anatomopathologic parameters, pTNM classification and 
prognostic staging on required ablative activity.
Patients and Methods: We studied retrospectively 
275 patients with DTC. All patients were treated with 
radioactive iodine (Iodine-131) after total thyroidectomy. 
Data were analyzed using statistical tools (Khi2 or 
ANOVA tests).
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Results: The highest activities were required when tumor 
size exceeded 6cm (P=0.012), when peri-thyroid fat was 
invaded (P<010-3) or when many cervical lymph node 
compartments were invaded (P<010-3). A comparable 
report was found with pTNM classification. In fact 
ablative activity increased beyond T3 (P=0.002) and 
N1a (P=0.039). No correlation was found with TNM 
prognostic staging.
Conclusions: Our study showed that we could predict 
a better ablative efficiency of iodine131 when tumor size 
is less than 6cm, lymphatic invasion involvement in one 
compartment and in the case of peri-thyroid fat integrity. 
These criterion correspond in pTNM classification to 
T<T3 and N<N1b classes.
P-011
Lymph Node Metastasis of Differenti-
ated Thyroid Cancer More Frequently 
Develops into Non-iodine-avid than 
Lung or Bone Metastasis
F. Feng, H. Wang
Department	of	Nuclear	Medicine,	Xinhua	Hospital,	Shanghai	
Jiao	Tong	University,	School	of	Medicine,	1665,	Kong	Jiang	
Rd,	Shanghai,	China
Background: Some lymph node (LN) metastases and 
distant metastases of differentiated thyroid carcinomas 
(DTCs) can develop non-iodine-avid as a poor prognostic 
factor. The present study was performed to evaluate 
the influencing factor of radioiodine (RAI) uptake in 
LN metastases and distant metastases in DTC patients.
Materials and Methods: This retrospective study 
included 121 DTC patients with LN metastases or 
distant metastases who were treated with 131I therapy 
after thyroidectomy from 2001 to the end of 2009 in 
our department. Non-iodine-avid metastases were 
diagnosed by 18F-fluorodeoxyglucose (FDG) positron 
emission tomography (PET), CT, MRI or surgery. 
Iodine avidity was determined by visual uptake in the 
metastatic site at post-therapeutic 131I WBS. Statistical 
analysis was performed by using SPSS software 
(version 15.0). Univariate and multivariate analysis 
were performed using t-test, chi-square test and binary 
variable logistic regressions model. P<0.05 was taken as 
statistically significant. 
Results: 121 patients with metastases included 75 (62.0%) 
women and 46 (38.0%) men; 51 (42.1%) patients were 
<45 years old and 70 (57.9%) patients were ≥45 years old 
(range: 5–80 years; mean age: 45.0 years); histologically, 
there were 104 (86.0%) papillary carcinomas, 17 (14.0%) 
follicular carcinomas. Totally 51 patients had non-iodine-
avid metastases. On univariate analysis, LN metastases 
were more frequently be non-iodine-avid that distant 
subgroup (χ2=4.338, P=0.037). However, there are not 
significant difference between lung and bone metastases 
(χ2=1.509, P=0.216). Binary variable logistic regressions 
model revealed four significant predictors of non-iodine-
avid occurrence: Papillary histology (OR=0.059; 95% CI 
0.010 to 0.037, P=0.001), age (OR=1.050; 95% CI 1.019 to 
1.082, P=0.001), metastasis time (OR=4.122; 95% CI 1.421 
to 11.894, P=0.000) and recurring time (OR=4.299; 95% CI 
2.132 to 7.685, P=0.000). Metastases in 13 patients taking 
up RAI developed non-131I-avid metastases after treated 
with 131I. Four patients recurring long time after 131I 
therapy all have non-iodine-avid metastases.
Conclusion: DTC metastases in LN more frequently 
developed to lose their ability to concentrate iodine 
than distant metastases, but bone metastases and lung 
metastases show the similar chance to be non-iodine-
avid. Old age, papillary histology, metastasis time and 
recurring times are predictor factors for non-iodine-avid 
metastases. 131I may potential predictor factors for non-
iodine-avid metastases.
P-012
The Outcome of Differentiated 
Thyroid Carcinoma Patients with Lung 
Metastases after Radiothyroablation 
with Iodine-131
G. Gunawan, B. Hidayat, B. Darmawan, 
A. H. S. Kartamihardja, J. S. Masjur
Department	 of	Nuclear	Medicine,	Hasan	Sadikin	Hospital,	
School	 of	Medicine,	 Padjadjaran	University,	 Bandung,	
Indonesia
Background: Thyroid cancer is the most common 
endocrine neoplasm. RAI therapy has been widely 
used for metastatic differentiated thyroid cancer (DTC). 
Metastases sites of DTC are lung and bone respectively. 
The aim of this study was to evaluate outcome of RAI 
therapy in lung metastatic DTC regarding its pattern 
and survival rate.
Materials and Methods: DTC patients with lung 
metastases were enrolled from 2005 – 2010. The subjects 
were divided into two groups based on uptake pattern 
of metastatic lesion: macro and micronodule. Outcome 
of RAI therapy was evaluated by serum thyroglobulin 
measurement and visually radioiodine uptake changes 
on post RAI therapy whole body scan or diagnostic 
I-131 whole body scan with minimal one year of follow 
up period. 
Results: There were 286 patients of DTC from 2005 – 
2010, 15 of them had lung metastases (age 9 – 61, mean 
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43.5; 13 female and 2 male). Histopathology result 
showed papillary thyroid cancer in 11 patients and 
follicular thyroid cancer in 4 patients. From all patients, 
there were 11 patients showing lung metastases and 
4 patients showed both lung and bone metastases. 
Micronodules were found in 10 of 11 patients with 
lung metastases and 2 of 4 patients with both lung and 
bone metastases. Most of the micronodules (9/11 and 
2/4) showed decreased serum thyroglobulin level and 
radioiodine uptake. Two patients showed no metastatic 
lesions on their last follow- up scan result (one patient 
in 2.5 years, while another patient in 6 years after their 
first radioiodine treatment).
Conclusion: Micronodule metastatic lesion show better 
response to RAI therapy.
P-013
Head Mass with Radioactivity Uptake 
in Patient with Thyroid Carcinoma
N. Nopriwan, B. Hidayat, B. Darmawan, 
A. S. H. Kartamihardja
Department	 of	Nuclear	Medicine,	Hasan	Sadikin	Hospital,	
School	 of	Medicine,	 Padjadjaran	University,	 Bandung,	
Indonesia
Introduction: Thyroid cancer is a tumor with unique 
presence. Good survival rate in the patient with thyroid 
tumor is common even when distance metastases occur. 
Site of metastases in this tumor are lung (49%), bone 
(25%) and other soft tissue (10%). Only 3 of 144 new 
cases diagnose with well- differentiated (DTC) have 
metastases to the brain in our department in the last 3 
years. All cases are female; 2 papillary and 1 follicular 
carcinoma. 
Treatment: One female patient has a history of lump 
in the neck within 9 years decided to have treatment 
when another mass in the head occur. The result from 
thyroid scan was enlargement of two lobes with un-
regular distributed of radioactivity, nodule in the lower 
part left lobes no uptake were present, the Mass on the 
left part of occipital bone with diameter 1 cm shown an 
uptake from radioactivity. Fine Needle Biopsy (FNAB) 
results conclude that the mass was metastases thyroid 
carcinoma. The Patient underwent total thyroidectomy 
with pathologic finding show papillary thyroid carcinoma 
variant follicular, follow by radiothyroablation protocol 
in our department with NaI-131 100 mCi and given oral 
dose 150 ug L-Thyroxin. Patient hospitalized for 6 day 
with dose rate still > 1 mRad/h. Whole body scan not 
performed in this patient because that reason. Six month 
later patient came again with a larger mass in the head 
after 1 month L-thyroxin discontinued. Laboratory finding 
show Thyroglobulin value: 148 ng/dl (N: 2-70 ng/dl), 
Anti Thyroglobulin: >3,000. Patient was decided to second 
round RAI NaI-131 150 mCi and given oral dose 150 ug 
L-Thyroxin. Patient hospitalized again for another 9 day 
with dose rate still> 1 mRad/h. Whole body scan not 
performed in this patient because that reason either. Six 
months later the mass became larger with diameter ± 3 
cm after 1 month L-Thyroxin discontinued. The laboratory 
result find that Thyroglobulin value was: 250 nag/dl (N: 
2-70 ng/dl) and Anti Thyroglobulin: >2,369. The patient 
then decided to give another session of RAI NaI 131 with 
dose 150 mCi followed with 150 ug L-Thyroxin. Then 
again patient was hospitalized for 9 day with dose rate 
still> 1 mRad/h. Whole body scan not performed in this 
patient because that reason either.
Discussion: Three session of high dose RAI NaI 
treatment did not affect the mass in the head which 
was still growing and laboratory finding (Tg and ATA) 
remain high. One of the main reasons was the range 
of internal radiation of beta from iodine 0.2-0.8 mm. It 
explains why not all of extra thyroid mass in the head 
was ablated. The bigger the mass affect, the long duration 
of stay from the treatment. Excision of extra thyroid mass 
in patients with a large diameter must be a consideration 
to improve the effectiveness of RAI treatment. 
P-014
Recent Status of Radioiodine Therapy 
for Patients with Primary Hyperthy-
roidism and Differentiated Thyroid 
Carcinoma in Bangladesh
S. Afroz, F. Begum, M. A. Taher
Bangladesh	Atomic	Energy	Commission,	Dhaka,	Bangladesh
Introduction: Radioiodine therapy (RIT) has been in use 
for last 7 decades since 1941 for hyperthyroidism and 
patients with Differentiated Thyroid Carcinoma (DTC) 
successfully. In Bangladesh, RIT was introduced on 1961, 
but its use has tremendously increased in last decade about 
30 times more than that was in early 1980s as in other 
countries for its proven safety and cost effectiveness. Society 
of Nuclear Medicine, Bangladesh established guidelines 
for RIT in hyperthyroidism and patients with DTC with 
taking consideration of common agreements of experts in 
Nuclear Medicine, medicine specialists, endocrinologists 
and consultant surgeons through National Workshop on 
Management of Thyroid Cancer and Thyrotoxicosis by 
Nuclear Medicine Technique-14 Aug 2002.
Objectives: To observe the outcome of fixed dose RIT 
in primary hyperthyroidism and different doses of 
radioiodine ablation therapy (RIAT) in DTC among 
Bangladeshi population.
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Materials and Methods: Meta-analysis of databases and 
registries for RIT of 3 peripheral Centers for Nuclear 
Medicine and one Institute in Bangladesh was done. 
During the year 2006 to 2010, total 2196 patients with 
primary hyperthyroidism and 1873 patients with DTC 
received RIT. All Nuclear Medicine Centers of our 
Country take the responsibilities of life long follow up 
of the patients after RIT, so, in these centers data about 
history, investigations and RIT and follow up were well 
preserved. Data of all these patients from registries were 
included in this study. RIT in small ranges of fixed dose 
in patients of Graves’ disease (GD) (131I, 8-12 mci), toxic 
multinodular goiter (TMNG) (fixed dose-131I -15 mci) 
and autonomous functioning toxic nodule (AFTN) (131I 
-15 mci) and different dose schedules of radioiodine (RI) 
for DTC were given. Doses of RI in DTC varied from 30 
mci to 250 mci. In thyroidectomized patients with DTC 
with significant remnants of thyroid tissue 30 mci/50 
mci was given. Patients with DTC without metastases 
received 75/100 mci doses depending on residual tissue. 
Patients with lymph nodes/lungs metastases were given 
150 mci and those with bony metastases received 200 
mci. Patients with brain metastases were given 250 mci 
with special care. All patients those received 50 mci and 
more were isolated in single cabin of a specified hospital 
for 6 days and those who received 30 mci were also 
confined to hospital for 2 days and also given in some as 
outpatients after satisfactory counseling. At follow –up, 
patients with DTC were assessed by doing serum TSH 
(as all patients are kept in TSH suppressive levothyroxine 
supplement), thyroglobulin (Tg) 3 monthly at first year 
of RIT and thereafter 6 monthly. Whole body Iodine scan 
(WBS) was done in each patient at first and second year 
of RIAT after withdrawal of levothyroxine for 3 weeks 
routinely. WBS was repeated after 5 years and whenever 
needed especially when Tg became high. Patients were 
considered disease free or as survivor when his serum 
Tg level <4 ng/ml (normal range-4-14 ng/ml) and 
subsequent two WBS were normal after getting single 
dose of radioiodine ablation therapy. Success rate of RIT 
in hyperthyroidism or remission of thyrotoxicosis was 
considered to attain euthyroidism or hypothyroidism. 
Persistence of hyperthyroid state after 6 months of RIT 
was considered as treatment failure and these patients 
needed subsequent RIT for remission. 
Results: Among 2196 hyperthyroid patients (Age range; 
11-85 years, mean age, 41±12 years), female to male 
ratio was 2:1. Patients with GD (79%), TMNG (15%) and 
AFTN (6%) had received RIT. Patients with GD received 
radioiodine at fixed dose of 8-12 mci and patients with 
TMNG and AFTN were given 15 mci of radioiodine. Similar 
treatment outcome was found in different centers (P>0.05). 
At 6 months follow up, 47% of GD remained in euthyroid 
state, 40% patients became hypothyroid and 13 % (failure 
rate of hyperthyroidism) remained still in hyperthyroid 
state. These patients with persistence hyperthyroid state 
received subsequent RIT in higher doses than the initial 
dose. After 24 months of follow up, all patients with GD 
became hypothyroid. In case of TMNG, euthyroid state 
was attained by 56% of treated patients, 14% patients 
became hypothyroid and treatment failure was noted 
in 30% cases at 24 months of follow up. At same follow 
up time, euthyroid state was observed in 75% cases of 
AFTN and 25% cases required double doses of RIT. About 
1873 patients with DTC were treated with radioiodine in 
mentioned centers during the last five years. Age range of 
patients with papillary carcinoma of thyroid (PCT) was 11-
78 years, mean age, 36±12 years. Ratio of PCT to follicular 
carcinoma of thyroid (FCT,) was 18:1. Age range of patients 
with FCT was 25-70 years, mean age, 50±20 years Majority 
patients (52%) with PCT referred to Nuclear Medicine 
Departments after total thyroidectomy without metastases 
and received 100 mci of RI and showed highest percentages 
(87%) of disease free survival. About 28% patients with PCT 
presented with cervical lymph nodes metastases, 2% with 
lungs metastases and 2% of cases of PCT with follicular 
variant showed bony metastases. About 55% of patients 
after receiving RIT showed disease free survival who had 
PCT presented with cervical lymph nodes metastases but 
had history of good cervical clearance surgery along with 
total thyroidectomy. About 12.5% of patients with FCT 
presented without metastases, 25% cases with cervical 
lymph nodes and or lungs metastases, 50% with bony 
metastases and 12.5% with brain metastases. Disease free 
survival was observed in 80% cases with FCT who were 
presented and treated without metastases, but 95% cases 
needed double or more doses. 
Conclusion: In retrospect from the given statistics it is well 
apparent that the success rate of RIT for hyperthyroidism 
varied from 70%-87% depending on disease categories at 6-24 
months of follow up. Disease free survival after 12- 48 months 
follow up was observed highest (87%) in patients presented 
with PCT without metastases who received 100 mci of 
radioiodine. About 55% of patients showed disease free 
survival who had PCT presented with cervical lymph nodes 
metastases. Multiple doses were needed in 95% patients with 
FCT with metastases. Finally it can be concluded that more 
affordable nuclear techniques are urgently needed with each 
passing year, as the cancer epidemic spreads in developing 
parts of the world like Bangladesh.
P-015
R o l e  o f  U l t r a s o n o g r a p h y, 
Radionuclide Scan and Fine Needle 
Aspiration Cytology in the Diagnosis of 
Malignancy in Solitary Thyroid Nodule
N. Akhter, M. F. Kabir
Department	of	Nuclear	Medicine,	Centre	for	Nuclear	Medicine	
and	Ultrasound,	Bangladesh
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Purpose: Ultrasonography (USG), Radio nuclide Scan 
(RNS) and Fine Needle Aspiration Cytology (FNAC), 
clearly all have particular application in the diagnosis 
of malignancy in solitary thyroid nodule. But there are 
drawbacks of each technique and the final answer to the 
problem is still elusive. This study aims to review the 
existing protocol and to compare the efficacy of USG, 
RNS and FNAC in appropriate selection of patients for 
surgery.
Materials and Methods: This cross sectional study 
included 50 patients with solitary thyroid nodule, 
were examined by USG, RNS and FNAC. All the study 
patients underwent thyroid surgery and their biopsy 
materials were sent for histopathological diagnosis. The 
diagnostic accuracies of all the modalities were then 
assessed against histopathological diagnosis.
 Results: The sensitivity of USG in diagnosing malignancy 
in solitary nodules was much lower (62.5%) than those 
of RNS (87.5%) and FNAC (75%), while the specificity 
of RNS was much lower (28.6%) compared to USG 
(88.1%) and FNAC (97.6%). The positive predictive 
value of USG was much lower (50%) than that of FNAC 
(87.5%). However, the PPV of RNS was staggeringly 
lower (18.9%). The NPV of three diagnostic modalities 
were over 90% and were almost comparable. The overall 
diagnostic accuracy of USG (84%) was nearer to that of 
FNAC (94%) but significantly higher than that of RNS 
(38%).
Conclusion: The current protocol could not effectively 
isolate benign from malignant disease. The problem of 
solitary thyroid nodule also demands special attention 
or revision of current protocol. We see that there is still 
a need for approaches that improve the yield of patient 
selection for surgery of solitary thyroid nodule especially 
in areas where iodine deficiency is endemic. 
P-016
Unusual Metastasis in Papillary 
Thyroid Carcinoma: A Case Report
H. Indrawati, B. Hidayat, B. Darmawan, 
A. Hasrayati, A. Nugraha, A. H. S. Kartamihardja, 
J. Masjur
Department	 of	Nuclear	Medicine,	Hasan	Sadikin	Hospital,	
School	 of	Medicine,	 Padjadjaran	University,	 Bandung,	
Indonesia
Introduction: Papillary thyroid carcinoma is the most 
common neoplasm in the thyroid gland and accounts for 
about 70% of all thyroid carcinomas. When the regional 
nodes are systemically examined, most patients with 
papillary carcinoma are found to have microscopic 
nodal metastases. Node metastases to other regions can 
be found although rarely reported. We report a case 
of papillary thyroid carcinoma with lymphogenous 
metastases on inguinal lymph nodes without any 
involvement of cervical nodes.
Case Report: A 55-y.o female underwent right thyroid 
lobectomy followed by external radiation in the year 
of 2000 in peripheral hospital. Nine years later, she 
complained of left groin mass. Cytology examination 
suggested metastasis from the thyroid. Since the bulky 
tumor was inoperable, the patient first underwent 
adjuvant chemotherapy with doxorubicin regimen. 
After six cycles of chemotherapy, the inguinal mass 
significantly shrunk and became operable. Total 
thyroidectomy and left inguinal lymphadenectomy were 
performed. Histopathology results showed papillary 
thyroid carcinoma and inguinal metastases. The patient 
was treated with I-131 150 mCi (5550 MBq). Post-RAI 
ablation scintigraphy showed pathological uptake in 
thyroid bed and left inguinal region.
Discussion: Papillary thyroid carcinoma usually spreads 
to cervical lymph nodes. The spreading to other regional 
lymph nodes is rarely reported. Mazzaferri and Young 
(1981) found recurrence rates is increasing approximately 
fivefold in patients over age 40 who were found to have 
regional nodal metastases at initial surgery. According to 
Maches A et al (2004) when lateral or mediastinal lymph 
node compartments are involved there is a possibility 
of cancer cell spread to corresponding lymphatic flow 
region, such as in the groin lymph node.
Conclusion: In differentiated thyroid carcinoma patients 
with any regional lymphadenopathy, distant metastasis 
of the primary tumor should always be considered.
P-017
Effect of Low Dose Radioiodine 
Therapy in Respect to Amount of 
Post-operative Thyroid Tissue (with 
Metastasis or Not)
A. K. M. Bari, F. Alam, T. Rahman
Thyroid	Medicine,	 Institute	 of	 Nuclear	Medicine	 and	
Ultrasound,	Dhaka,	Bangladesh
Introduction: Management of patients with differentiated 
thyroid cancer with low dose radio-iodine with 
significant amount of remnant of thyroid tissue, serum 
thyroid stimulating hormone level relatively lower and 
variable amount of I-131 uptakes to avoid complications 
of iodine-131 thyroid ablation therapy referred to INMU. 
Objective: To determine the effect of low dose 
radioiodine therapy in destroying the amount of thyroid 
tissue remaining after surgery. To reduce the treatment 
cost and avoidance of hospital admission for isolation. 
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Design: Prospective study. 
Materials and Methods: Low dose iodine-131 (29mci-
50mci) was used to ablate post-operative thyroid remnants 
in 15 patients with differentiated thyroid cancer. Serum 
thyroid stimulating hormone (TSH), serum thyroglobuline 
(Tg), thyroid USG, thyroid scan and uptake test were done 
in all patients before radioiodine therapy. All patients 
were followed up with thyroxin suppression of thyroid 
stimulating hormone after ablation. Follow- up of patients 
was done by measuring serum Tg (off thyroxin) and whole 
body scans (WBS). 
Results: The surgical procedure was total/near-total 
thyroidectomy in 82.3% and 48.5% total thyroidectomy 
with radical neck dissection and subtotal or hemi-
thyroidectomy in 11.7%. Histology was papillary 
carcinoma in 94.15% of patients and 5.8% was follicular 
carcinoma of thyroid. With more than one low dose 
I-131of 10 patients (58.8%), remnant ablation was 
achieved in 7(70%), where as in 1 patient WBS (whole 
body scan) shows focally increased uptake in right lobe 
after two low dos therapy in 2 patients no follow up 
whole body scan and thyroglobulin (Tg) done. 5 patients 
out of 6 patients with significant activity in pre-therapy 
scan and good amount of tissue in ultra sonogram 
show good response to low dose I-131 ablation therapy 
(complete ablation). In one patient two subsequent 
28mCi and 29 mCi doses fail to ablation. In this patient 
WBS shows focal increased uptake in right lobe (positive) 
but thyroglobulin (Tg) less than one. Ablations by one 
low dose in 5 patients, 3 patients (60%) show effective 
or complete ablation and rest two patients do not follow 
up adequately.
Conclusions: The use of multiple low doses of I-131 
therapy can be effective as large dose therapy. Low dose 
therapy ensures low cost I-131 therapy in differentiated 
thyroid carcinoma and avoidance of hospitalization. 
P-018
I-131 Therapy for Pediatric Hyperthy-
roid: A Clinical Experience in Nuclear 
Medicine Department of Dr. Hasan 
Sadikin Hospital, Indonesia
A. S. Erwin, B. Hidayat, A. H. S. Kartmihardja
Department	of	Nuclear	Medicine,	Dr.	Hasan	Sadikin	Hospital,	
Universitas	Padjadjaran,	Bandung,	Indonesia
Background: Incidence of hyperthyroid is very rare in 
pediatric, more than 95% of cases is caused by Graves 
disease. There are three therapeutic options for pediatric 
Graves’ disease: antithyroid drugs, radioiodine ablation 
and surgery. Because of its higher rate of significant 
remission in pediatric Graves’ disease, antithyroid 
drugs are the first line of therapy. Recently, there 
are many reports about effectiveness of radioiodine 
therapy for pediatric Graves’ patients. Pediatric Graves’ 
hyperthyroidism may have poor therapeutic responses 
to I-131 when getting delayed ablations or just have been 
treated with antithyroid drugs. In this report we wish 
to describe our experience in using radioiodine therapy 
for pediatric hyperthyroid patients.
Materials and Methods: A retrospective study was 
done in 701 hyperthyroid patients. Among them, there 
were seven pediatric patients (1%) who underwent 
radioiodine ablation therapy based on hyperthyroidism 
criteria (goiter with increased thyroid hormones, 
decreased TSH sensitive level, Tc-99m pertechnetate 
diffuse uptake) in our department in the period of 
November 2008 to November 2010. All those pediatric 
patients were given I-131 therapy with doses of 4-8 mCi. 
Their clinical responses and laboratory examination 
were followed-up until the time of three months after 
radioiodine therapy.
Results: The subjects consisted of six girls and one boy, 
aged between 12-20 years old. Five of the patients had 
been treated with antithyroid drugs. Hyperthyroidism 
was diagnosed between one month and six years. 
After three months follow up, there were two drop out 
patients; one patient was not achieving time of the three 
months follow up yet. Four patients showed significantly 
clinical improvement manifestation after radioiodine 
therapy with decreasing in their serum thyroid hormones 
levels although still not achieved normal values yet. All 
of those four patients needed no longer special medical 
attentions and antithyroid therapy but still needed 
reablation therapy.
Conclusion: Radioiodine is a convenient and effective 
therapy for pediatric hyperthyroid.
P-019
Quantitative Study of the Different 
Protocols Analysis for Excess Radia-
tion Absorbed Doses from Radioiodine 
Treatment of Hyperthyroidism in 
Bangladesh
Hossain Md. Nahid Hossain, K. Afroz, 
Md. Nurul Islam, T. A. Biman, F. Begum, 
Md. Anwar-Ul-Azim
Nuclear	Medicine,	 Institute	 of	 Nuclear	Medicine	 and	
Ultrasound,	Shahbag,	Dhaka,	Bangladesh
Introduction and Objective: Radioiodine therapy 
is the first choice for treatment of hyperthyroidism 
because it is considered safe, inexpensive and is 
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convenient for the patient almost without side effects. 
Even though radioiodine therapy of hyperthyroidism 
using 131-I has been performed for more than 60 years, 
the technique of treatment; prescribing the activity 
differs from country to country and even from hospital 
to hospital within the same country. A number of 
protocols have been suggested and used for calculation 
the activity to be administered to the patients for the 
radioiodine treatment of hyperthyroidism; application 
of these protocols may result in excess dose of the 
hyperthyroid patients. The main objective of this 
study was to carry quantitative study of the different 
protocols analysis for excess radiation absorbed doses 
of hyperthyroid patients.
Materials and Methods: To illuminate such differences 
50 radioiodine treatments for hyperthyroidism at the 
Institute of Nuclear Medicine and Ultrasound in 
Dhaka, Bangladesh have been analyzed. Comparative 
absorbed dose calculations were carried out assuming 
that the individual patients had also been treated 
according to different protocols in current use. The 
measurement of thyroid uptake were performed 2, 
24 and 48 hrs after administration of the 0.4 MBq 
radioiodine 131-I uptakes to each patient. Also some 
patients 131-I uptake were measured after 5 and 6 
days for using single uptake method for calculating 
the absorbed dose. Thyroid mass and effective half-life 
were also calculated and the variations in the thyroid 
doses were analyzed.
Results: The results show that the method used for 
calculation of the administered activity in radioiodine 
therapy is differ from optimized in the patients. In 
Bangladesh, all hospitals used fixed administered 
activity for the treatment for hyperthyroidism. For 
that reason, most of the patients were treated with an 
unnecessarily high activity, as a mean factor of 2.75 
times too high and in individual patients up to 7 times 
too high from my study, leading to an unnecessary 
radiation exposure both for the patient, the family 
and the public. The protocols, which have not taken 
into account the thyroid mass, and the effective half-
life of 131I of the individual patient, showed a higher 
degree of deviation from the required thyroid dose. 
This is not acceptable with general radiation protection 
principles. 
Conclusion: Using higher activity for treatment of 
hyperthyroidism than required will also extend the patients 
stay at the hospital, increase risk for the exposure to others 
and thus increase the costs for the care. Unnecessarily 
high activity will also impose more long-lasting radiation 
protection restriction relative to family members when 
the patient returns home. More effort should be made 
worldwide to conform these protocols in use and thus 
decrease unnecessary radiation dose to individual patients 
and their families.
P-021
Effect of Single Dose of Radioiodine 
Therapy on Volume Reduction of the 
Thyroid Gland in Hyperthyroidism
S. Khan, F. Alam, F. Begum, N. Nahar, S. Sultana, 
Z. Jabin
Department	 of	 Nuclear	Medicine,	 Institute	 of	 Nuclear	
Medicine	and	Ultrasound,	Dhaka,	Bangladesh
The aim of the present study was to see the reduction of 
thyroid volume and its relation to thyroid status. In this 
study 10-12 mci of radioactive iodine was used for the 
treatment of hyperthyroidism and volume measurement 
of thyroid gland before and after the treatment was 
done by ultrasonogram. Total 117 patients from July 
2009 to June 2010 were studied at Institute of Nuclear 
Medicine and Ultrasound, BSMMU campus. Patients 
with diffuse toxic goiter, toxic multinodular goiter and 
single toxic nodular goiter of any age after puberty 
were included in this study. All the patients were under 
went through physical examination, thyroid scan with 
99mTc, radioactive iodine uptake test and FT4, TSH level. 
Thyroid volume was measured by Ellipsoid method 
of ultrasonography. Patients were followed up after 3 
months and 6 months by evaluating thyroid volume and 
hormone assay. In this study 86 patients were having 
diffuse toxic goiter and 31 had nodular goiter. Of these 
31 had nodular goiter, 10 had single nodule and 21 had 
multiple nodule. Mean volume of the thyroid gland 
was 24 ml, which reduced to 14 ml at 1st follow- up and 
became 9.1 ml after 2nd follow- up. Volume reduction 
of thyroid gland was 42% at 3 months and 66.1% at 6 
months. Single dose of radioactive iodine therapy is very 
effective for diffuse toxic goiter, toxic multinodular goiter 
and single toxic nodule.
P-022
Graded Empirical I-131 Therapy in 
Differentiated Cancer of Thyroid - Is 
There an Ideal Dose?
A. Shinto, C. Joseph
NM	and	PET,	KMCH,	CBE,	India
Introduction: The consensus about optimal activities 
of I-131 for thyroid remnant ablation has not yet been 
achieved. The aim of this study was to compare ablation 
rates obtained with different I-131 activities.
Patients and Methods: The study included 102 patients 
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divided into four groups according to I-131 activities 
given after total thyroidectomy for papillary thyroid 
cancer: group A [42 patients who received 897 MBq], 
group B [23 patients who received 1470 MBq], group C 
[18 patients who received 1847 MBq], and group D [17 
patients who received 4432 MBq]. Ablation outcome 
was assessed by whole-body scan in hypothyroid state 
6-9 months after ablation and finally 18-21 months after 
the treatment.
Results: The rate of successful ablation was similar in 
the group of patients who received 24 and 40 mCi (75 
and 71.2%, respectively). The higher rate of ablation 
was achieved in the groups treated with 50 and 120 
mCi of radioiodine (87.69 and 90.74%, respectively). The 
ablation rates at the first follow-up examinations (59.5, 
67.2, 73.9, 80.6%) were lower than at second control study 
(75.0, 71.2, 87.7, 90.7%) in all groups. Time required for 
thyroid remnant ablation seems to be >=18 months. 
Conclusion: Our study indicates that activity of 50 mCi 
seems to be optimal to achieve a successful ablation rate 
(approximately 90%). Low I-131 activities are acceptable 
for lower risk patients because of satisfactory ablation 
rate (>70%), lower expense, and minimal radiation 
burden to patients as well as lower radiation exposure
P-023
Role of Tc-99m Pertechnetate Thyroid 
Scintigraphy in Detecting Etiology of 
Congenital Hypothyroidism
A .  H u d a ,  H .  B a s u k i ,  B .  D a r m a w a n , 
A. H. S. Kartamihardja, J. S. Masjhur
Department	 of	Nuclear	Medicine,	Hasan	Sadikin	Hospital,	
School	 of	Medicine,	 Padjadjaran	University,	 Bandung,	
Indonesia
Introduction: Recently hypothyroidism screening in 
newborns is a routine procedure in several developed 
countries in the world. Congenital hypothyroidism (CH) 
is one of endocrine diseases in newborns that require early 
diagnosis to avoid adverse effects on neurological and 
intellectual functions. Diagnosis can be made by newborn 
screening using serum thyroid stimulating hormones-
sensitive (TSHs) and the etiology can be differentiated using 
thyroid scintigraphy. Dr. Hasan Sadikin hospital is one of 
12 hospitals in Bandung that joins national programme for 
hypothyroidism screening in newborns from year of 2000.
Aim: To investigate the etiology pattern of CH 
detected through newborn screening. Materials and 
Materials and Methods: Dry technique sampling and 
radioimmunoassay (RIA) were used to measure serum 
TSHs from 118,920 newborns. CH was defined when 
high serum level of TSHs from the newborn was found. 
Thyroid scintigraphy was performed after intravenous 
injection of 18.5 – 37 MBq Tc-99m pertechnetate (based 
on surface area) on hypothyroid infants.
Results: Twenty eight infants were diagnosed having 
primary congenital hypothyroidism by high level of 
serum TSHs. Scintigraphy results were classified as 
: agenesis (absence of uptake), dyshormonogenesis 
(presence of uptake), ectopic (uptake outside thyroid 
beds), hemiagenesis (uptake in one side of thyroid 
beds). From the 28 hypothyroid infants, 12 were found 
to have agenesis, 2 hypoplasia, 2 hemiagenesis, 8 of 
ectopic thyroid gland, and 4 patients with suspected 
dyshormonogenesis.
Conclusion: Small percentage of CH was found from 
serum TSHs. Thyroid scintigraphy allows the evaluation 
of the etiology of CH pattern with thyroid agenesis as 
the most frequent cause.
P-024
Incremental Value of I-131-SPECT/
CT Fusion Imaging Over I-131-WBS 
in the Management of patients with 
Differentiated Thyroid Carcinoma
ZY. Ye, H. Wang
Nuclear	Medicine,	Xinhua	Hospital,	Shanghai,	China
Objective: 131I whole-body scintigraphy (WBS) is an 
important exam during 131I therapy of the differentiated 
thyroid carcinoma (DTC), which plays a significant 
role in detecting differentiated thyroid tumors and 
metastases, evaluating the therapeutic effect and helping 
to make further clinical management. However, it is 
hard to localize parts of radioactive accumulations 
because WBS is a planar imaging which lacks of anatomic 
landmarks. Besides, sometimes it is also difficult to 
differentiate between lesion accumulation, physiological 
accumulation and contamination. By technique of 
attenuation correction, 131I-SPECT/CT can make 
fusion imaging involving anatomical structure and 
functional information, and provide reliable evidence to 
the accurate location or qualitative analysis of thyroid 
carcinoma and its metastases. This retrospective study 
estimated the incremental value of 131I-SPECT/CT 
fusion imaging over WBS in the management of patients 
with DTC.
Materials and Methods: Total 82 DTC patients 
underwent both WBS and SPECT/CT imaging after they 
acquired radioiodine therapy. The scans were interpreted 
by two experienced nuclear medicine physicians and an 
experienced radiologist. According to the pathological 
results, other imaging characters and clinical follow-
up, accumulations were separated to: 1) benign ones, 
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including physiological accumulations (nasopharynx, 
thyroid remnant, salivary glands, digestive tract, 
bladder and diffuse liver accumulation), inflammation 
accumulation or radioactive contamination; 2) malignant 
ones, including remnant tumor, recurrence or metastases; 
3) undefined ones, accumulations could not be verified 
as benign or malignant. The capacity of location or 
qualitative analysis of SPECT/CT imaging compared 
with WBS was analyzed and the impact of SPECT/CT 
imaging on diagnosis of metastases, clinical stage and 
therapeutic strategy were evaluated.
Results: 203 accumulations were detected by WBS. 
89 of them (43.84%) were located by WBS, which was 
verified by SPECT/CT imaging. Thyroid remnant and 
bone were the most accurate regions, reached accuracy 
of 74.24% (44/66) and 62.86% (22/35) respectively. WBS 
determined 52 benign accumulations, 36 malignant ones 
and 115 uncertain ones while the number of SPECT/
CT imaging were respectively 94, 79 and 30. There was 
a significant difference of the uncertain accumulations 
between SPECT/CT imaging and WBS (t=77.51, 
P=0<0.01). Besides, 6 none-radioiodine avid metastases 
were detected by SPECT/CT imaging. Among all 82 
patients, 14 (17.07%) were changed about the diagnosis of 
metastasis; 5 (6.1%) were changed about the clinical stage 
and 23 (28.05%) were changed about the therapeutic 
strategy.
Conclusion: 131I-SPECT/CT fusion imaging has incremental 
value in differentiating radioactive accumulations, detecting 
of non-radioiodine avid lesions, improving accuracy of 
diagnosis of DTC and adjusting therapeutic strategy. 
131I-SPECT/CT fusion imaging is a better method than 
131I-WBS in the management of patients with DTC.
P-025
Empirical Dual Dose Iodine-131 
Therapy for Graves’ Disease
K. Makhdomi 
Department	 of	Radiology,	Aga	Khan	University	Hospital,	
Nairobi,	Kenya
Introduction: Various methods have been used to 
calculate the dose of Iodine-131 for therapy of Graves’ 
disease, including calculating the dose per gram of tissue 
or using empirical calculations. No conclusive evidence 
has been noted suggesting the superiority of any of these 
dose calculation techniques. We used a simple algorithm 
for a dual dose technique for the therapy.
Materials and Methods: Ninety three consecutive 
patients diagnosed with Graves’ disease on clinical 
findings, biochemistry and a technetium thyroid scan 
who were send for Iodine-131 therapy were enrolled 
for this study. Results of the thyroid scan – technetium 
thyroid uptake - and clinical examination – size of the 
goiter - were used to determine the dose of I-131 for 
therapy, either 15 or 20 mCi. All patients with a thyroid 
uptake of 1 to 5% and/or a goiter of Grade II or greater 
were administered 20 mCi, whereas all other patients 
– uptake greater than 5% and goiter less than Grade 
II - received 15 mCi. All patients were followed up for 
a minimum of one year post-therapy to evaluate their 
thyroid status.
Results: At the end of one year post-therapy seventy-four 
patients were euthyroid, fourteen hypothyroid and five 
hyperthyroid. This meant that eighty-eight of the ninety-
three patients (95%) responded to the therapy. Out of 
these responders 16% had become hypothyroid by the 
end of the first year. There was no significant difference 
in the response rate and incidence of hypothyroidism at 
the end of one year between the two groups treated with 
15 or 20 mCi of I-131.
Conclusion: It is concluded that the above empirical 
technique of dose calculation for I-131 therapy for 
Graves’ disease using two doses -15 and 20 mCi – reveals 
very good response rates, comparable with those in 
literature using various dose calculation techniques. 
This simple dose calculation technique can thus provide 
a good alternative to these other techniques.
P-026
Complications to the mother and child 
with Thyroid Cancer after the Treat-
ment with I-131
A. Fard-Esfahani, S. Saber, M. Hadifar, 
B. Fallahi, D. Beiki, M. Eftekhari, M. Saghari, 
A. Takavar
Research	Institute	for	Nuclear	Medicine,	Tehran	University	
of	Medical	Science,	Iran	
Radioiodine (I-131) has been widely used in the treatment 
of differentiated thyroid carcinoma. Since radiation can 
carry a known risk of mutagenic abnormalities, we decided 
to study the outcome of pregnancy in females with DTC 
and evaluate the genetic risks and health status of their 
offspring. We retrospectively studied the medical records 
of these patients in our Institute from 1999 to 2004. A total 
of 1110 women were hospitalized for treatment with high 
doses of 131I, at least 3700MBq. During this period, 653 
of these women were in their reproductive period. A 
hundred of them, who had at least one pregnancy after 
131I treatment, were studied. These women had a total 
of 126 pregnancies (1-6 pregnancies each) after treatment 
and 101 pregnancies before treatment. We also reviewed 
the131I dose administered last, as well as the cumulative 
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dose of 131I. Our results show that the incidence of 
abortions before 131I treatment was 16.83% (all were 
spontaneous abortions) and increased to 26.19%after 
131I treatment (15.87% induced and 10.3% spontaneous 
abortions). Spontaneous abortions were decreased. There 
was no significant difference between the mean last 131I 
dose and the cumulative dose in patients with or without 
a history of abortions. Mean interval between the last 
dose of 131I treatment and abortions versus the last dose 
and live childbirths showed a significant difference. 
All children had normal birth weight. Three congenital 
anomalies: Down’s syndrome, cardiac abnormalities 
and macrocephaly were diagnosed. Three episodes of 
intrauterine death were also recorded. In conclusion, our 
findings indicate that in women with DTC, treated with 
high doses of131I: a) There was no evidence of increased 
spontaneous abortions, b) Increasing the interval between 
the last dose of 131I treatment and time to pregnancy might 
be beneficial for decreasing the entire risk of abortions and 
c) It appears that 131I treatment had no obvious adverse 
effects on the risk of congenital anomalies.
P-027
Lacrimal Duct Obstruction after 
Iodine-131 Therapy in Patients with 
Differentiated Thyroid Cancer
A.Takavar,  S .  Farzanefar,  B.  Fal lahi , 
D. Beiki, M. Eftekhari, M. Saghari, S. Saber, 
A. Emamiardekani, M. Majdi 
Research	Institute	for	Nuclear	Medicine,	Tehran	University	
of	Medical	Science,	Iran
Aim: 131I has been widely used in treatment of 
differentiated thyroid carcinoma for almost 70 years. 
During this period many complications such as 
lacrimal gland dysfunction have been established. 
This study argues a new complication “symptomatic 
or asymptomatic lacrimal duct obstruction”. 
Materials and Methods: 81 patients (162 eyes) treated 
with more than 100 mCi 131I were categorized in 4 
groups based on received cumulative dose and were 
evaluated in a historical cohort study. In addition 17 
(34 eyes) age and sex matched persons were selected as 
control group. Using dacryoscintigraphy, patients and 
control group were evaluated for partial or complete 
lacrimal duct obstruction. The data on different groups 
of patients were compared with the data of control 
group. Fisher’s exact and Mann-Whitney U tests 
were applied for analyses of categorical and numeric 
variables, respectively. The analyses were considered 
significant with P<0.05.
Results: 18% of exposed eyes (29 out of 162) and 9% of 
control eyes (3 out of 34) had evidences of lacrimal duct 
obstruction on the scan images. Among the patients 
treated with less than 300 mCi of 131I, 12.8% (5 out of 
39) had asymptomatic lacrimal duct obstruction and 
2.6% (1 out of 39) had symptomatic obstruction. These 
values for patients treated with more than 300 mCi were 
19% (8 out of 42) and 35.7% (15 out of 42), respectively. 
Mean cumulative 131I dose that lead to lacrimal duct 
obstruction was 429±264 mCi. This value was 273±173 
mCi for the patients without obstruction (P<0.05).
Conclusion: This study confirms lacrimal duct 
obstruction as a complication of 131I therapy. The 
symptomatic form of this complication occurs mainly 
in cumulative dose more than 300 mCi.
P-028
Comparison of Different Techniques 
for Assessing the Thyroid Functional 
Status in Patients with Hyperthyroid-
ism
Q. Siraj, I. Shammeri, U. Afzal, R. Ahned, 
S. Renilson
Department	of	Nuclear	Medicine,	Farwania	Hospital,	Kuwait	
I-131 thyroid uptake determination is the measurement 
of the fraction of an administered amount of radioactive 
iodine that accumulates in the thyroid at a selected 
time following ingestion. Thyroid uptake can also 
be determined by using intravenously administered 
Tc-99m pertechnetate and a gamma camera. To our 
knowledge, these three widely utilized methods of 
assessing thyroid functional status have not previously 
been compared in the same group of patients. The 
study attempts to evaluate and validate the technetium 
uptake parameters against the established technique 
of I-131 uptake. The aim of the study was to assess 
the reliability of the technetium uptake parameters 
compared with the radioiodine probe measurements 
since this would result in not only reduction of radiation 
burden to the patient but would obviate the need for 
the patient to attend the department on two separate 
days. The study also investigates the reasons for the 
differences observed between the thyroid uptake probe 
and the gamma camera pertechnetate measurements. 
The report includes data from a total of 100 patients 
investigated at the nuclear medicine departments of 
the Farwania Hospital Kuwait (50 patients) and St. 
Mary’s Hospital Portsmouth (57 patients). 24-hr I-131 
uptake was performed using a scintillation probe as 
part of pre-radioiodine therapy assessment. Thyroid 
scintigraphy with Tc-99m pertechnetate was performed 
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in all of the patients and quantified by estimating the 
20-minute Tc-99m pertechnetate uptake and thyroid-
to-background ratio at 20 minutes. The results of the 
different measurements were evaluated by regression 
analysis. The correlation between the 20-min thyroid 
uptake and the thyroid-to-background ratio at 20-min 
was 0.84, between Tc-99m pertechnetate uptake and 
the I-131 uptake was 0.61 and that between the thyroid-
to-background ratio and the I-131 uptake was 0.53. The 
correlation between these parameters and the serum 
thyroid hormone levels is also discussed. We conclude 
that pertechnetate uptake measurements can sensitively 
and fairly accurately document thyroid functional status. 
The pertechnetate uptake techniques are comparable in 
their accuracy and definitely more accurate than the 24-
hr uptake measurement of I-131.
P-029
The Advantages of Routine Radio-
thyroablation in Well-differentiated 
Thyroid Carcinoma Patients
H. Indrawati, B. Hidayat, B. Darmawan, 
A. H. S. Kartamihardja, J. S. Masjur
Department	 of	Nuclear	Medicine,	Hasan	Sadikin	Hospital,	
School	of	Medicine,	Padjadjaran	University,	Bandung,	Indonesia
Introduction: Routine radiothyroablation following total 
thyroidectomy remains controversial in well-differentiated 
thyroid cancer (DTC). Thyroid remnant is commonly found 
even after total thyroidectomy. In our institution (Dr. Hasan 
Sadikin Hospital), we use routine RAI therapy for thyroid 
remnant ablation and unsuspected metastases that was 
subsequently seen from post- therapy whole body scan. 
The purpose of this study was to evaluate the advantages 
of routine ablation in DTC patients.
Materials and Methods: The retrospective study was 
conducted on patients’ data that were diagnosed with DTC 
and subsequently treated with routine ablation therapy 
after total thyroidectomy from January 2009-December 
2010. Routine ablation was given 6-8 weeks after total 
thyroidectomy. I-131 therapeutic dose was varied between 
80-200 mCi (2960 MBq-7400 MBq). WBS and SPECT/CT post 
therapy were performed when patients were discharged to 
evaluate pathological extrathyroidal uptake of I-131.
Results: A total of 133 patients (103 female, 30 male, 13 – 72 
years old) were included in this study. Papillary carcinoma 
was diagnosed in 95 patients and the rest had follicular 
carcinoma. There were pathological extrathyroidal 
uptakes of I-13 in 33 cases. Twenty-six of them were 
unsuspected with pathological extrathyroid uptake, 
while seven others were referred with prior history of 
distant metastases. Two of the 7 cases did not show any 
pathological uptake of I-131 as predicted before. Imaging 
was able to show more metastases lesions in the other 5.
Conclusion: I-131 routine ablation exhibits advantages 
in differentiated thyroid carcinoma patients to detect 
unsuspected distant metastases and provide guidance 
for more suitable management.
P-030
Electrolyte Imbalance in Patients 
During Radioablation Na I-131: Case 
Report
A. Huda, B. Hidayat, B. Darmawan, H. Sundawa
Department	 of	Nuclear	Medicine,	Hasan	Sadikin	Hospital,	
School	of	Medicine,	Padjadjaran	University,	Bandung,	Indonesia
High TSHs serum level is required for effective 
radioiodine uptake in every patient who will receive RAI 
therapy. The condition can be achieved by administering 
rhTSH or levothyroxine withdrawal for several weeks. 
Levothyroxine withdrawal may cause hypothyroidism 
and discomfort for the patients. One adverse event of 
hypothyroidism is electrolyte imbalance. We report 
2 cases of hypothyroidism with electrolyte imbalance 
during RAI treatment in the period of 2009-2011. One 
follicular thyroid carcinoma (FTC) patient 70 years age 
and 1 papillary thyroid carcinoma (PTC) patient 61 years 
of age. All patients received cumulative doses of NaI-131 
(14.8 GBq). Before RAI therapy, TSHs serum level was 
22.37 uIU/mL for the FTC patient and 53.5 uIU/mL for 
the PTC patient. RAI therapy still given to FTC patient 
regardless of suboptimal TSHs serum level because 
of levothyroxine withdrawal for more than 4 weeks 
already. After 24 hours of RAI therapy isolation, both 
patients complained of nausea and vomiting without 
signs of dehydration. Followed by a decreased level of 
consciousness (1 patient with somnolence and the other 
with stupor accompanied by seizures). Neurological 
abnormalities were not found by physical examination at 
the time. Decreased electrolyte serum level (Na/sodium: 
103 mEq/L; K/potassium: 3.2 mEq/L) was found on 
the FTC patient as well as on the PTC patient (Na/
sodium: 120 mEq/L; K/potassium: 3.6 mEq/L). These 
conditions were corrected by saline and KCl infusion, 
and early levothyroxine administration. Improvement 
of patients’ general conditions were documented one 
day after correction.
Discussion: The nature of electrolyte imbalance due to 
hypothyroidism remains unknown. In our cases, electrolyte 
imbalance is caused by levothyroxine withdrawal. 
Levothyroxine is usually given after discharging patients 
from isolation (in our institution, usually 5 days after 
RAI treatment). But in these cases, levothyroxine was 
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administered concomitant with electrolyte imbalance 
correction (2 day after RAI treatment). However the 
pathological radioiodine uptake was still documented by 
after RAI therapy whole body scans at the thyroid bed. Age 
may also affect electrolyte balance in elderly patients that 
they have increased risk of body fluid and sodium changes. 
This condition when combined with other conditions like 
hypothyroidism will increase risk of fluid and electrolyte 
imbalance. In our cases, both patients were elderly with no 
underlying heart and kidney disease. Hyponatremia can be 
corrected with electrolyte infusion and early levothyroxine 
administration.
Conclusions: Hypothyroid state due to levothyroxine 
withdrawal in long periods (> 4 weeks) prior to RAI 
therapy can cause electrolyte imbalance, especially 
in elderly patients. Levothyroxine administration 
immediately after electrolyte imbalance correction can 
significantly improve patient condition. There are no 
effects of early levothyroxine after RAI to the remnant 
disease tissue uptake.
P-031
Therapeutic Response Evaluation on 
Hyperthyroidism Using a Fixed Dosed 
of I-131
H. Kurniawati, B. Hidayat, B. Darmawan, A. H. 
S. Kartamihardja, J. H. Masjur
Department	 of	Nuclear	Medicine,	Hasan	Sadikin	Hospital,	
School	 of	Medicine,	 Padjadjaran	University,	 Bandung,	
Indonesia
Introduction: Euthyroid condition is the ideal expected 
post therapy result in hyperthyroidism, but there is 
still no established therapeutically method that can 
achieve said condition. I-131 has been known as one 
of the methods to manage this condition. However, 
controversy over the optimum dose of I-131 therapy is 
still debated. The objective of this study is to evaluate 
therapeutic response after fixed dosed I-131 therapy in 
our department.
Materials and Methods: This retrospective study 
was carried out during January 2010 until January 
of 2011. The inclusion criteria were all subjects 
received I-131 for the first time with a fixed dose 
of 8 mCi, diffused enlargement and high uptake of 
Tc-99m. Therapy response was evaluated based on 
the patient’s clinical state and or their laboratory 
results 3 months after the therapy. Therapeutic 
response categorized successful if thyroid hormones 
within normal value and/or improvement of clinical 
state, also if thyroid hormones below normal value 
with better clinical state, but it categorized partial 
response when thyroid hormones still high (above 
normal value) with improvement clinical state and no 
response if there were no changes both on laboratory 
result and clinical state.
Results: There were 127 patients receiving a fixed 
dose I-131 therapy of 8 mCi during January 2010 
to January 2011. As many as 87 underwent routine 
examination on third month. However the other 
40 did not, therefore cannot be considered for 
analysis. The patients were between 12 to 63 years 
of age. From the 87 patients, 46 (52.87%) were still 
considered in a hyperthyroid condition, 20 (22.98%) 
were hypothyroid, and 21 (24.13%) were euthyroid. It 
means about 47.11% patients have good response on 
third month. From the 46 who were a hyperthyroid 
condition, a second ablative therapy were done on 43 
patients, while the other 3 did not get ablative therapy 
due to improvement of clinical state so they need 
more evaluation before getting second radioablation 
therapy.
Conclusion: Further studies regarding fixed dose I-131 
therapy in Indonesia are still needed. There are other 
factors that influence the success of therapy, therefore 
theurapeutic response should be evaluated.
P-032
Influence of Metastases Characteristic 
to Survival Rate in Papillary Thyroid 
Carcinoma
N. Nopriwan, B. Hidayat, B. Darmawan, 
A. H. S. Kartamihardja
Department	 of	Nuclear	Medicine,	Hasan	Sadikin	Hospital,	
School	 of	Medicine,	 Padjadjaran	University,	 Bandung,	
Indonesia
Introduction: Differentiated Thyroid Carcinoma (DTC) 
is a slow growing cancer with rare occurrence of distant 
metastases. The median survival of DTC patient with 
brain metastases is 12 months. Surgical resection is 
suggested for this kind of patient followed by RAI 
therapy. We presented two cases of patients with 
brain metastases of Papillary thyroid carcinoma (PTC) 
who undergone RAI therapy and thyroid hormone 
suppression only. Both patients were unable to undergo 
surgery because of unresectable mass.
Case 1: A 34-year-old female patient was diagnosed 
with PTC with left temporal lobe and lung metastases 
from the first post therapy whole body scanning. At the 
time, the patient was given 5 times of RAI therapy with 
a cumulative dose of 750 mCi. The patient is still alive 
after 5 years follow up period. 
Case 2:  A 51-year-old female was diagnosed 
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with PTC follicular variant with left parietal lobe 
metastases. The patient had already been given RAI 
therapy for 3 times with a cumulative dose of 450 
mCi. The patient is still alive after 2.5 years follow 
up period.
Discussion: Papillary thyroid carcinoma is the most 
common type of differentiated thyroid carcinoma. Few 
reports have shown that brain metastases are a rare 
complication of thyroid carcinoma. It is reported that 
metastatic lesions from DTC may be less differentiated 
than primary tumor, thus not accumulating radioactive 
iodine. In our cases, both post-RAI therapy whole 
body scan showed radioiodine uptake in the brain 
metastatic lesion. This may be favorable factor, which 
is supported by the fact that there were decrease of 
serum thyroglobulin and antithyroglobulin antibody 
level.
Conclusion: These cases suggest that survival rate of 
DTC patients with brain metastases is influenced by 
metastatic lesion's ability to take radioiodine.
P-033
The Outcome of Differentiated 
Thyroid Carcinoma Patients with Lung 
Metastases after Radiothyroablation 
with Iodine-131G
Gunawan,  B.  Hidayat ,  B.  Darmawan, 
A. H. S. Kartamihardja, J. S. Masjur
Department	 of	Nuclear	Medicine,	Hasan	Sadikin	Hospital,	
School	 of	Medicine,	 Padjadjaran	University,	 Bandung,	
Indonesia
Background: Thyroid cancer is the most common 
endocrine neoplasm. RAI therapy has been widely 
used for metastatic differentiated thyroid cancer (DTC). 
Metastases sites of DTC are lung and bone respectively. 
The aim of this study was to evaluate outcome of RAI 
therapy in lung metastatic DTC regarding its pattern 
and survival rate.
Materials and Methods: DTC patients with lung 
metastases were enrolled from 2005 – 2010. The subjects 
were divided into two groups based on uptake pattern 
of metastatic lesion: macro and micronodule. Outcome 
of RAI therapy was evaluated by serum thyroglobulin 
measurement and visually radioiodine uptake changes 
on post RAI therapy whole body scan or diagnostic 
I-131 whole body scan with minimal one year of follow 
up period.
Results: There were 286 patients of DTC from 2005 – 2010, 
15 of them had lung metastases (age 9 – 61, mean 43.5; 
13 female and 2 male). Histopathology result showed 
papillary thyroid cancer (PTC) in 11 patients and follicular 
thyroid cancer (FTC) in 4 patients. From all patients, there 
were 11 patients showing lung metastases and 4 patients 
showed both lung and bone metastases. Micronodules 
were found in 10 of 11 patients with lung metastases and 
2 of 4 patients with both lung and bone metastases. Most 
of micronodules (9/11 and 2/4) showed decreased serum 
thyroglobulin level and radioiodine uptake. Two patients 
showed no metastatic lesions on their last follow- up scan 
result (one patient in 2.5 years, while another patient in 6 
years after their first radioiodine treatment). 
Conclusion: Micronodules metastatic lesion show better 
response from RAI therapy. 
P-034
Assessment of Organification Defect 
in Thyroid Gland in Children with 
Goitrous Hypothyroidism 
A. Narasimhan
Department	 of	 Nuclear	Medicine,	 G.K.N.M	Hospital,	
Coimbatore,	India
Aim: To assess the utility of Perchlorate discharge test 
using Gamma camera in Hypothyroid children with 
increased trapping function in Tc99m Thyroid scan.
Materials and Methods: The study included 16 patients 
from June 2009 to June 2011. They were in the age group 
of 22 days to 15 Years. 6 were males and 10 were Females. 
All patients underwent Tc 99m Thyroid scan prior to 
the study which showed enlarged thyroid gland with 
increased trapping function (Tc99m uptake - > 4%). 6 
Patients were not started on Tablet Thyroxin prior to 
the study and rest of the patients had stopped Thyroxin 
for 1 month prior to the study. 8 patients had elevated 
levels of Antimicrosomal antibody. All patients were 
administered between 90 to 125uCi of I-131 orally and 
static images for 1 minute were acquired after 2 hours. 
A standard with similar activity was prepared and static 
images were taken for similar time intervals. ROI was 
drawn over the thyroid region and around the activity 
area in the standard images and counts were obtained. 
% Tracer uptake by the Thyroid gland was calculated.1 
Gram of potassium perchlorate was then administered 
orally and images were acquired at varying time 
intervals up to 2 hours. %  uptake by the thyroid gland 
in the 2-hour post perchlorate image was calculated. A 
reduction in tracer uptake in the post perchlorate images 
by > 10 % as compared to the pre-perchlorate image was 
considered as positive.
Results: Out of 16 patients, 13 patients had positive post 
perchlorate test which is suggestive of organification 
defect in the Thyroid gland. The remaining 3 patients 
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had Iodine deficiency or Iodine avid Goiter as there 
was no reduction in thyroid uptake in post perchlorate 
images. Out of 13 patients, 8 patients had elevated 
Antimicrosomal antibodies which were suggestive of 
congenital hypothyroidism.
Conclusion: Perchlorate discharge test using Gamma 
camera (in centers where thyroid probe is not available) 
is useful in diagnosing organification defects in the 
thyroid gland. Perchlorate discharge test using gamma 
Camera should be routinely done in hypothyroid 
children with increased trapping function in the 
thyroid scan as these patients require lifelong thyroxin 
supplementation.
P-035
NaI-131 Radioablation for Well-differ-
entiated Thyroid Cancer at Dr. Hasan 
Sadikin General Hospital
D. Nugraha, B. Darmawan, A. H. S. Kartamihardja 
Department	of	Nuclear	Medicine,	Hasan	Sadikin	Hospital,	School	
of	Medicine,	Padjadjaran	University,	Bandung,	Indonesia
Background: Thyroid cancer is the most common cancer 
among all endocrine malignancies. The incidence of 
thyroid cancer range 1.2 and 2.6 in men and from 2.0 
to 3.8 in women per 100.000 individual with wide 
variability between different countries. The aim of this 
study was to evaluate the usefulness of NaI-131 radio 
ablation for well- differentiated thyroid cancer at Dr. 
Hasan Sadikin General Hospital. 
Materials and Methods: This study was a retrospective 
study. Subjects were grouped into two groups based 
on histopathology finding, papillary thyroid carcinoma 
(PTC) and follicular thyroid carcinoma (FTC). All 
subjects received 2960 - 9250 MBq NaI-131 and isolated. 
Following up was done at 6 and 12 months after radio 
ablation by using Thyroglobulin (Tg), Antithyroglobulin 
antibody (ATA) serum level and diagnostic whole body 
scan. The criteria of good response if Tg level < 3 ng/mL, 
negative ATA and negative whole body scan.
Results: During period of time July 2008 - July 2009, 
there were 126 subjects underwent for NaI-131 radio 
ablation, 24 (19%) were male and 102 (81%) female, aged 
16 - 84 years. Good response was observed in 12 (9.5%), 
no response in 52 (41.3%), while 62 (49.2%) dropped 
out. The highest incidence 57 (45.3%) was occurred in 
the age group of 45-64 years and the lowest incidence 
7 (5.6%) was in the age group of 65-84 years. Based on 
histopathological, there were 92 (73%) PTC and 34 (27%) 
FTC.
Conclusion: The incidence of well-differentiated thyroid 
cancer among females is higher than males and the 
age predilection is between 45-64 years old. Based on 
histopathological finding PTC is the most common 
malignancy in the thyroid gland. After a follow-up for 
a year, large numbers are found to be unresponsive. 
Further evaluation should be done to find out very high 
drop out patients.
P-036
Signi f icance of  E levated Ant i 
Thyroglobulin Antibody Levels in 
Differentiated Thyroid Cancer Patients
J. Irfan, M. A. Khan, S. Fatima
Nuclear	 Medicine,	 Nuclear	 Medicine	 Oncology	 and	
Radiotherapy	Institute,	Islamabad,	Pakistan
Differentiated (papillary and follicular) thyroid 
carcinoma (DTC) is generally characterized by an 
indolent course with low morbidity and mortality and is 
among the most curable cancers The long term survival 
of differentiated thyroid cancer warrants the long term 
follow up follow-up of patients with DTC. In this study 
the significance of increased anti Thyroglobulin antibody 
in long term follow of thyroid cancer patient was studied. 
Total of 56 patients (37 females and 19 males, mean age: 
46.9±23.1) were enrolled as study group. All patients 
had diagnosis of low-risk thyroid cancer. After total 
thyroidectomy all patients had baseline Thyroglobulin, 
Anti Thyroglobulin antibodies and neck ultrasound. 
All patients were given ablative dose of I-131 when 
serum TSH was >30 ng/ml. Patients were followed up 
6 monthly with I-131 whole body scan, Thyroglobulin, 
Anti Thyroglobulin antibodies and neck ultrasound. 
Successful ablation was defined as minimal or no neck 
uptake on I-131 WB scan, no remnant tissue on thyroid 
USG with Tg levels <2 ng/ml and Anti-Tg < 20 ng/ml 
when TSH30 mIU/ml.
Results: In our study group 42 out of 56 patients were 
re-evaluated at 6 months after therapy. Whole-body 
I-131 (WB) scan, thyroid ultrasonography (USG), Tg, 
anti TG Ab measurements were performed at each 
follow-up visit. Out of total study population 24 patients 
had raised baseline Anti Thyroglobulin antibody levels. 
Serial follow up in all 24 showed gradual decline in Anti 
Thyroglobulin antibody levels with successive ablative 
therapies. Out 32 remaining patients 18 developed 
subsequent rise in Anti Thyroglobulin antibody levels 
which was treated with I-131 treatment dose with 
good response to therapy in 10 cases. Out of thse 18 
patients 3 had negative whole body scan normal Tg and 
elevated anti thyroglobulin antibody levels. PET-CTof 
these patients showed FDG avid lesions. Based on the 
above study it was concluded that Anti Thyroglobulin 
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antibody levels in DTC patients carry a significant clinical 
significance.
P-037
Rare Case of Metastasis to Pituitary 
from follicular Thyroid Carcinoma
B. M. Magsombol, S. P. Thang, A. K. Padhy
Department	of	Nuclear	Medicine	and	PET,	Singapore	General	
Hospital,	Singapore
Background: Pituitary metastasis occurs in only 1-3% 
of patients with malignant tumors and is considered 
a rare occurrence. Breast cancer is the most common 
primary tumor that metastasizes to the pituitary, 
followed by lung malignancy. Most of the patients with 
pituitary metastases are asymptomatic and therefore 
differentiation of pituitary metastases from other 
primary tumors is often difficult both clinically and 
radiologically.
Summary: A 64-year-old woman presented with 15-
year history of euthyroid multinodular goiter and 
background of left renal cell carcinoma treated with 
radical nephrectomy was admitted with non-specific 
symptoms of cough, breathlessness, and diarrhea, loss 
of appetite and loss of weight over several weeks. CT 
neck of thorax, abdomen and pelvis was performed 
during her inpatient stay showed multiple findings of 
an enlarged pituitary fossa mass, asymmetric enlarged 
thyroid lobe (left more than right) compressing and 
narrowing the trachea, large lytic lesion at L4 vertebral 
body, and two discrete small pulmonary nodules. 
Areas of increased tracer uptake were seen at the right 
proximal humerus, L3-L5 vertebrae and subtrochanteric 
region of the left femur. Prior to discharge, the patient 
underwent L4 vertebral body biopsy, which revealed a 
metastatic carcinoma. After discharge, patient presented 
again to A&E with bitemporal hemianopia. Repeat 
MRI scan showed increased in pituitary mass size with 
increased bowing and distortion of the optic chiasm, as 
well as indentation on the floor of the third ventricle. 
Following this, she underwent a total thyroidectomy 
and a trans-sphenoidal resection of the pituitary mass. 
Histopathology was officially signed out as both 
papillary and follicular thyroid carcinoma whilst that 
of the resected pituitary tumor was that of metastatic 
follicular thyroid carcinoma. Post therapy I-131 whole 
body scan after oral administration of 250mCi of 
radioiodine showed functioning metastases in the region 
of the pituitary fossa, left parotid region and anterior 
neck.
Conclusion: Although pituitary metastasis is a rare 
incidence, this should be excluded in patients with 
hypopituitary symptoms and known thyroid cancers. 
Radioiodine ablation is highly indicated after a pituitary 
metastasis resection as complete tumor resection may 
not be possible by surgery alone.
P-038
Efficacy of I131 in the Treatment of 
Differentiated Thyroid Carcinoma: 
Results of 655 Patients at the Nuclear 
Medicine and Oncology Center Bach 
Mai Hospital
M. T. Khoa, T. D. Ha, Phn S. An, N. T. Trang, 
N. T. The, T. H. Binh, D. X. Truong, T. K. Mai, 
D. H. Tran, Phan Sy An
The	Nuclear	Medicine	 and	Oncology	Center,	 Bach	Mai	
Hospital,	Hanoi,	Vietnam
Background: According to IAEA recommendations, 
I131 has been used in the management of patients with 
differentiated thyroid carcinoma (DTC) in Vietnam since 
1998. Previous clinical experience gained from treatment 
of large number of Vietnamese DTC patients with I131 
was limited. This study is designed to evaluate the 
clinical outcomes of I131 therapy and thereby to define 
the role of I131 in the treatment of DTC.
Materials and Methods: From January 2002 to August 
2009, 655 DTC patients were treated with I131. Location: 
The Nuclear Medicine and Oncology Center, Bach Mai 
Hospital, Hanoi, Vietnam. Retrospective (from January 
2002 to January 2008) and prospective research. All 
patients were diagnosed with DTC (histopathological 
confirmation) underwent total thyroidectomy and 
lymphadenectomy and followed with I131 treatment 
were reported every 1, 3 months after treatment. Patients 
were excluded who were suspected of having 1) TSH < 
30 mU/ml, 2) currently using iodine product, 3) renal 
and liver failure, 4) pregnancy or breast feeding, 5) lost 
data. Radiopharmaceuticals: NaI liquid or capsule.
Results: The male: female ratio was 1:4. The mean age 
was 41,29 ± 15,73 and 40,05 ± 13,65 in male and female 
respectively, with majority being <45 years old (60,8%). 
Subjects included papillary 82,9%, follicular 7,9%, mixed 
9,2% types. I131 doses were 30mCi, 50mCi, and 100 
mCi. If metastases were discovered, the patient could be 
treated with higher doses and several times. Changes in 
remnant thyroid volume, I131 scan, Tg and anti Tg level 
were evaluated. Histopathology types, remnant thyroid 
volume, I131 concentration are significant prognostic 
factors. Ablation success rate after surgery: 33,3 %, 60,1% 
79,2% in 30mCi, 50mCi, 100 mCi subgroup respectively. 
At 6th month after treatment, all the parameters were 
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reduced remarkably and the vital laboratory tests (blood 
count, liver and renal function) were normal. Complete 
response 18,3%, partial response 58,3%, poor response 
20% and restraint 3,4%. There is no severe complications 
even in subgroup who have been treated several times 
with high cumulative dose > 300 mCi.
Conclusions: The Nuclear Medicine and Oncology 
Center has successfully applied radioiodine therapy for 
DTC patients and the outcome is promising. Papillary 
thyroid cancer has better response than follicular and 
mixed type. I131 is a safe and effective treatment and 
can be used for remnant ablation (after thyroidectomy), 
for recurrent and metastatic DTC with good effects and 
acceptable side effects.
P-039
Radionuclide Therapy in Russia: 
A Status Report from the Largest 
Radionuclide Therapy Centre in Russia
V. Krylov, A. Tsyb
Department	of	Radionuclide	Therapy,	Medical	Radiological	
Research	Center,	Obninsk,	Russia
Russia is a pioneer in peaceful use of atomic energy. In 
1954, the first ever Obninsk NPP came into operation. 
In the 1950s, the USSR assigned top priority to nuclear 
development, however a sequence of adverse events 
such as Chernobyl accident, collapse of the Soviet 
Union, painful economic adjustment, has thrown 
Russia back. The nuclear renaissance has prompted 
a renewed interest in peaceful nuclear technology, 
particularly in medicine. This is a thriving field 
for international cooperation, research and know-
how development, and an attractive investment 
opportunity. MRRC is the largest Radionuclide 
Therapy Centre in Russia. In the following 2012 it will 
celebrate the 50-year-old anniversary. MRRC consist 
of three big so-called Sectors: Clinical Radiology and 
Nuclear Medicine, Experimental Radiology, Radiation 
Epidemiology. Sector of Experimental Radiology 
is experimental facilities to carry out fundamental 
and experimental investigations. Sector of Radiation 
Epidemiology focuses their investigation in the field 
of radiological protection, health effects of radiation. 
Sector of Clinical Radiology and Nuclear Medicine 
is the biggest. It has the hospital on 400 beds. In the 
hospital there is a large diagnostic complex, including 
SPECT, MRI, CТ and set of laboratories, pathology and 
clinical departments, such as Radionuclide Therapy, 
Radiation and Surgical Treatment, Radiation Therapy, 
Radiosurgery, Hematologic, Urologic, Gynecologic 
diseases, Chest and Breast Cancer and others.
The Radionuclide Therapy department is the largest in 
Russia. They began using radiotherapeutics about 40 years 
ago. Trends and Methods of Radionuclide Therapy in 
MRRC: (1) Radioiodine Therapy in differentiated thyroid 
cancer (131I): MRRC treats more than 1500 thyroid cancer 
patients a year (ablation + metastases treatment). Over 
8000 patients have received radioiodine in the past five 
years. Treatment of lung metastases from thyroid cancer 
result in complete response in 71.4% partial response 
–22.2%, no effect –6.3%. Follow Up Time: 10 - year Survival 
Rate 79.3%. (2) Radioiodine Therapy for thyrotoxicosis 
(131I): More than 700 patients a year received radioiodine. 
Over 3000 patients have received radoiodine in the past 
five years, 90% of them are cured of thyrotoxicosis. 
(3) Radionuclide therapy for bone metastases (153Sm, 
89Sr): Annually more than 150 patients received 
radiotherapeutics, such as 89Sr chloride as competitive 
antagonist to Calcium and domestic therapeutic 
Samarium -153 Oxabiphore, RF Patent No 2162714 
dd 20.06.00. Effectiveness of Russian product meets 
international standards. Permanent pain relief, slower 
progression, lower intake or no analgesic medication, 
better quality of life are resulted in the treatment with 
the above therapeutics. Clinical effect demonstrates 
in 60-80% of patients. Best results were obtained in 
patients with breast and prostate cancer. (4) Prostate 
Cancer Interstitial Radiation Therapy (Brachytherapy): 
Effectiveness: 76% - 92% depending on the progression 
stage and prognosis. (5) 252Cf – brachytherapy: exclusive 
advanced technology of treatment of tumors of oral 
cavity. (6) Innovative drugs under development: 188Re 
OEDP– OxiEthylidenDiPhosphonate and 188Re –
zoledronate to treat patients with bone metastases. An 
entire pharmaceutical line is conceivable for interstitial, 
intracavitary, and systemic therapy both in oncology, 
rheumatology and cardiology. Now Russian Government 
began to pay much attention to the development of 
nuclear medicine in the country. This moment is very 
convenient for intensification of international cooperaion 
in the field of nuclear medicine. MRRC is a good and 
powerful platform for development of such cooperation.
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